View Filing Data

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
Document and Entity Information - USD ($) $ in Thousands	Dec. 28, 2013	Feb. 03, 2014	Jun. 29, 2013
Document and Entity Information [Abstract]
Document Type	10-K
Document Period End Date	Dec. 28, 2013
Amendment Flag	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2013
Current Fiscal Year End Date	--12-28
Entity Central Index Key	0001000228
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Registrant Name	HENRY SCHEIN INC
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Common Stock, Shares Outstanding		85,440,027
Entity Public Float			$ 8,303,174

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 28, 2013	Dec. 29, 2012
Current assets:
Cash and cash equivalents	$ 188,616	$ 122,080
Accounts receivable, net of reserves of $78,298 and $75,240	1,055,216	1,015,194
Inventories, net	1,250,403	1,203,507
Deferred income taxes	63,865	64,049
Prepaid expenses and other	276,565	299,547
Total current assets	2,834,665	2,704,377
Property and equipment, net	275,888	273,458
Goodwill	1,635,005	1,601,046
Other intangibles, net	417,133	462,182
Investments and other	461,945	292,934
Total assets	5,624,636	5,333,997
Current liabilities:
Accounts payable	824,495	787,658
Bank credit lines	29,508	27,166
Current maturities of long-term debt	5,441	17,992
Accrued expenses:
Payroll and related	216,629	207,381
Taxes	145,161	132,774
Other	329,429	299,738
Total current liabilities	1,550,663	1,472,709
Long-term debt	450,233	488,121
Deferred income taxes	198,674	196,814
Other liabilities	139,526	125,314
Total liabilities	2,339,096	2,282,958
Redeemable noncontrolling interests	497,539	435,175
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding	0	0
Common stock, $.01 par value, 240,000,000 shares authorized, 85,622,452 outstanding on December 28, 2013 and 87,850,671 outstanding on December 29, 2012	856	879
Additional paid-in capital	318,225	375,946
Retained earnings	2,398,267	2,183,905
Accumulated other comprehensive income	67,849	52,855
Total Henry Schein, Inc. stockholders' equity	2,785,197	2,613,585
Noncontrolling interests	2,804	2,279
Total stockholders' equity	2,788,001	2,615,864
Total liabilities, redeemable noncontrolling interests and stockholders' equity	$ 5,624,636	$ 5,333,997

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 28, 2013	Dec. 29, 2012
Current assets:
Accounts receivable, reserves	$ 78,298	$ 75,240
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	240,000,000	240,000,000
Common stock, shares outstanding (in shares)	85,622,452	87,850,671

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Income Statement [Abstract]
Net sales	$ 9,560,647	$ 8,939,967	$ 8,530,242
Cost of sales	6,904,633	6,432,454	6,112,187
Gross profit	2,656,014	2,507,513	2,418,055
Operating expenses:
Selling, general and administrative	1,978,960	1,873,360	1,835,906
Restructuring costs	0	15,192	0
Operating income	677,054	618,961	582,149
Other income (expense):
Interest income	12,853	13,394	15,593
Interest expense	(27,538)	(30,902)	(30,377)
Other, net	2,325	2,735	1,942
Income before taxes, equity in earnings of affiliates and loss on sale of equity investment	664,694	604,188	569,307
Income taxes	(190,891)	(187,858)	(180,212)
Equity in earnings of affiliates	10,194	7,058	15,561
Loss on sale of equity investment	(12,535)	0	0
Net income	471,462	423,388	404,656
Less: Net income attributable to noncontrolling interests	(39,908)	(35,312)	(36,995)
Net income attributable to Henry Schein, Inc.	$ 431,554	$ 388,076	$ 367,661
Earnings per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 5.02	$ 4.44	$ 4.08
Diluted (in dollars per share)	$ 4.93	$ 4.32	$ 3.97
Weighted-average common shares outstanding:
Basic (in shares)	85,926	87,499	90,120
Diluted (in shares)	87,622	89,823	92,620

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Statement of Income and Comprehensive Income [Abstract]
Net income	$ 471,462	$ 423,388	$ 404,656
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	9,474	33,347	(2,310)
Unrealized gain (loss) from foreign currency hedging activities	95	2,865	(618)
Unrealized investment gain (loss)	(100)	414	347
Pension adjustment gain (loss)	4,871	(5,451)	(6,238)
Other comprehensive income (loss), net of tax	14,340	31,175	(8,819)
Comprehensive income	485,802	454,563	395,837
Comprehensive income attributable to noncontrolling interests:
Net income	(39,908)	(35,312)	(36,995)
Foreign currency translation (gain) loss	654	(904)	889
Comprehensive income attributable to noncontrolling interests	(39,254)	(36,216)	(36,106)
Comprehensive income attributable to Henry Schein, Inc.	$ 446,548	$ 418,347	$ 359,731

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]	Noncontrolling Interests [Member]
Beginning Balance at Dec. 25, 2010	$ 2,412,957	$ 919	$ 601,014	$ 1,779,178	$ 30,514	$ 1,332
Beginning Balance, shares (in shares) at Dec. 25, 2010		91,939,477
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	368,142	$ 0	0	367,661	0	481
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	(1,421)	0	0	0	(1,421)	0
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	(618)	0	0	0	(618)	0
Unrealized investment gain (loss), net of tax impact	347	0	0	0	347	0
Pension adjustment gain (loss), net of tax impact	(6,238)	0	0	0	(6,238)	0
Dividends paid	(457)	0	0	0	0	(457)
Other adjustments	45	0	0	0	0	45
Initial noncontrolling interests and adjustments related to business acquisitions	4,155	0	4,155	0	0	0
Change in fair value of redeemable securities	(224,133)	0	(224,133)	0	0	0
Shares issued to 401(k) plan - Value	5,798	$ 1	5,797	0	0	0
Shares issued to 401(k) plan - Shares		93,204
Repurchase and retirement of common stock - Value	(200,002)	$ (31)	(60,609)	(139,362)	0	0
Repurchase and retirement of common stock - Shares		(3,179,188)
Stock issued upon exercise of stock options, including tax benefit - Value	41,765	$ 9	41,756	0	0	0
Stock issued upon exercise of stock options, including tax benefit - Shares		941,701
Stock-based compensation expense - Value	36,932	$ 2	36,930	0	0	0
Stock-based compensation expense - Shares		175,980
Shares withheld for payroll taxes - Value	(2,990)	$ (1)	(2,989)	0	0	0
Shares withheld for payroll taxes - Shares		(43,092)
Liability for cash settlement stock-based compensation awards	(659)	$ 0	(659)	0	0	0
Ending Balance at Dec. 31, 2011	2,433,623	$ 899	401,262	2,007,477	22,584	1,401
Ending Balance, shares (in shares) at Dec. 31, 2011		89,928,082
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	388,585	$ 0	0	388,076	0	509
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	32,443	0	0	0	32,443	0
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	2,865	0	0	0	2,865	0
Unrealized investment gain (loss), net of tax impact	414	0	0	0	414	0
Pension adjustment gain (loss), net of tax impact	(5,451)	0	0	0	(5,451)	0
Dividends paid	(430)	0	0	0	0	(430)
Initial noncontrolling interests and adjustments related to business acquisitions	(390)	0	(1,189)	0	0	799
Change in fair value of redeemable securities	(53,769)	0	(53,769)	0	0	0
Repurchase and retirement of common stock - Value	(299,883)	$ (39)	(88,196)	(211,648)	0	0
Repurchase and retirement of common stock - Shares		(3,937,054)
Stock issued upon exercise of stock options, including tax benefit - Value	104,122	$ 19	104,103	0	0	0
Stock issued upon exercise of stock options, including tax benefit - Shares		1,889,872
Stock-based compensation expense - Value	37,313	$ 3	37,310	0	0	0
Stock-based compensation expense - Shares		277,339
Shares withheld for payroll taxes - Value	(23,027)	$ (3)	(23,024)	0	0	0
Shares withheld for payroll taxes - Shares		(307,568)
Liability for cash settlement stock-based compensation awards	(551)	$ 0	(551)	0	0	0
Ending Balance at Dec. 29, 2012	$ 2,615,864	$ 879	375,946	2,183,905	52,855	2,279
Ending Balance, shares (in shares) at Dec. 29, 2012	87,850,671	87,850,671
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	$ 432,032	$ 0	0	431,554	0	478
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	10,128	0	0	0	10,128	0
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	95	0	0	0	95	0
Unrealized investment gain (loss), net of tax impact	(100)	0	0	0	(100)	0
Pension adjustment gain (loss), net of tax impact	4,871	0	0	0	4,871	0
Dividends paid	(487)	0	0	0	0	(487)
Other adjustments	(90)	0	(90)	0	0	0
Initial noncontrolling interests and adjustments related to business acquisitions	534	0	0	0	0	534
Change in fair value of redeemable securities	(41,039)	0	(41,039)	0	0	0
Repurchase and retirement of common stock - Value	(300,251)	$ (31)	(83,028)	(217,192)	0	0
Repurchase and retirement of common stock - Shares		(3,072,942)
Stock issued upon exercise of stock options, including tax benefit - Value	53,962	$ 7	53,955	0	0	0
Stock issued upon exercise of stock options, including tax benefit - Shares		743,651
Stock-based compensation expense - Value	35,527	$ 3	35,524	0	0	0
Stock-based compensation expense - Shares		349,804
Shares withheld for payroll taxes - Value	(22,500)	$ (2)	(22,498)	0	0	0
Shares withheld for payroll taxes - Shares		(248,732)
Liability for cash settlement stock-based compensation awards	(545)	$ 0	(545)	0	0	0
Ending Balance at Dec. 28, 2013	$ 2,788,001	$ 856	$ 318,225	$ 2,398,267	$ 67,849	$ 2,804
Ending Balance, shares (in shares) at Dec. 28, 2013	85,622,452	85,622,452

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Statement of Stockholders' Equity [Abstract]
Net income attributable to redeemable noncontrolling interests	$ 39,430	$ 34,803	$ 36,514
Foreign currency translation gain (loss) attributable to Redeemable noncontrolling interests	(654)	904	(889)
Unrealized gain (loss) from foreign currency hedging activities, tax benefit (tax)	26	(654)	94
Unrealized investment gain (loss), tax benefit (tax)	66	(310)	(215)
Pension adjustment gain (loss), tax benefit (tax)	(1,336)	2,187	1,534
Stock issued upon exercise of stock options, tax benefit	$ 18,410	$ 31,638	$ 7,246

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net income	$ 471,462	$ 423,388	$ 404,656
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	128,035	125,322	115,896
Accelerated amortization of deferred financing costs	6,203	0	0
Loss on sale of equity investment	12,535	0	0
Stock-based compensation expense	35,527	37,313	36,932
Provision for losses on trade and other accounts receivable	5,189	4,407	6,156
Provision for (benefit from) deferred income taxes	(11,514)	10,072	(19,319)
Stock issued to 401(k) plan	0	0	5,798
Equity in earnings of affiliates	(10,194)	(7,058)	(15,561)
Distributions from equity affiliates	16,529	14,499	14,883
Other	20,790	14,193	6,352
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(45,110)	(73,925)	36,204
Inventories	(48,087)	(193,585)	(44,155)
Other current assets	15,747	(62,390)	(10,493)
Accounts payable and accrued expenses	67,063	115,863	17,276
Net cash provided by (used in) operating activities	664,175	408,099	554,625
Cash flows from investing activities:
Purchases of fixed assets	(60,215)	(51,237)	(45,176)
Payments related to equity investments and business acquisitions, net of cash acquired	(182,363)	(220,238)	(149,403)
Payments related to sale of equity investment	(13,364)	0	0
Proceeds from sales of available-for-sale securities	0	9,225	2,600
Other	(10,663)	(7,354)	(1,243)
Net cash provided by (used in) investing activities	(266,605)	(269,604)	(193,222)
Cash flows from financing activities:
Proceeds from (repayments of) bank borrowings	2,175	(32,185)	13,316
Proceeds from issuance of long-term debt	678,781	155,132	3,101
Debt issuance costs	(1,372)	(1,482)	(2,847)
Principal payments for long-term debt	(729,977)	(40,722)	(33,722)
Proceeds from issuance of stock upon exercise of stock options	35,553	72,485	34,519
Payments for repurchases of common stock	(300,251)	(299,883)	(200,002)
Excess tax benefits related to stock-based compensation	8,141	17,819	8,765
Distributions to noncontrolling shareholders	(19,224)	(21,284)	(10,055)
Acquisitions of noncontrolling interests in subsidiaries	(9,800)	(20,481)	(170,199)
Other	0	0	(90)
Net cash provided by (used in) financing activities	(335,974)	(170,601)	(357,214)
Effect of exchange rate changes on cash and cash equivalents	4,940	6,902	(7,253)
Net change in cash and cash equivalents	66,536	(25,204)	(3,064)
Cash and cash equivalents, beginning of period	122,080	147,284	150,348
Cash and cash equivalents, end of period	$ 188,616	$ 122,080	$ 147,284

Significant Accounting Policies

12 Months Ended

Dec. 28, 2013

Accounting Policies [Abstract]

Significant Accounting Policies

Note 1 – Significant Accounting Policies

Nature of Operations

We distribute health care products and services primarily to office-based health care practitioners with operations or affiliates in the United States, Australia, Austria, Belgium, Canada, China, the Czech Republic, France, Germany, Hong Kong SAR, Iceland, Ireland, Israel, Italy, Luxembourg, Mauritius, the Netherlands, New Zealand, Portugal, Slovakia, South Africa, Spain, Switzerland, Thailand and the United Kingdom.

Principles of Consolidation

Our consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates, which are greater than or equal to 20% and less than or equal to 50% owned or investments in unconsolidated affiliates of less than 20% in which we have the ability to influence the operating or financial decisions, are accounted for under the equity method. See Note 6 for accounting treatment of Redeemable noncontrolling interests. Certain prior period amounts have been reclassified to conform to the current period presentation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fiscal Year

We report our results of operations and cash flows on a 52-53 week basis ending on the last Saturday of December. The years ended December 28, 2013 and December 29, 2012 consisted of 52 weeks and the year ended December 31, 2011 consisted of 53 weeks.

Revenue Recognition

We generate revenue from the sale of dental, animal health and medical consumable products, as well as equipment, software products and services and other sources. Provisions for discounts, rebates to customers, customer returns and other contra-revenue adjustments are recorded based upon historical data and estimates and are provided for in the period in which the related sales are recognized.

Revenue derived from the sale of consumable products is recognized when products are shipped to customers. Such sales typically entail high-volume, low-dollar orders shipped using third-party common carriers. We believe that the shipment date is the most appropriate point in time indicating the completion of the earnings process because we have no post-shipment obligations, the product price is fixed and determinable, collection of the resulting receivable is reasonably assured and product returns are reasonably estimable.

Revenue derived from the sale of equipment is recognized when products are delivered to customers. Such sales typically entail scheduled deliveries of large equipment primarily by equipment service technicians. Some equipment sales require minimal installation, which is typically completed at the time of delivery.

Revenue derived from the sale of software products is recognized when products are shipped to customers. Such software is generally installed by customers and does not require extensive training due to the nature of its design. Revenue derived from post-contract customer support for software, including annual support and/or training, is recognized over the period in which the services are provided.

Revenue derived from multiple element arrangements, and the related deferral of such revenue (which is insignificant to our financial statements), is recognized as follows. When we sell software products together with related services (i.e., training and technical support) we allocate revenue to the delivered elements using the residual method, based upon vendor-specific objective evidence (“VSOE”) of the fair value of the undelivered elements, or defer it until such time as vendor-specific evidence of fair value is obtained. Multiple element arrangements that include elements that are not considered software consist primarily of equipment and the related installation service. Effective December 26, 2010 we allocate revenue for such arrangements based on the relative selling prices of the elements applying the following hierarchy: first VSOE, then third-party evidence (“TPE”) of selling price if VSOE is not available, and finally our estimate of the selling price if neither VSOE nor TPE is available. VSOE exists when we sell the deliverables separately and represents the actual price charged by us for each deliverable. Estimated selling price reflects our best estimate of what the selling prices of each deliverable would be if it were sold regularly on a standalone basis taking into consideration the cost structure of our business, technical skill required, customer location and other market conditions. Each element that has standalone value is accounted for as a separate unit of accounting. Revenue allocated to each unit of accounting is recognized when the service is provided or the product is delivered.

Revenue derived from other sources including freight charges, equipment repairs and financial services, is recognized when the related product revenue is recognized or when the services are provided.

Cash and Cash Equivalents

We consider all highly liquid short-term investments with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Outstanding checks in excess of funds on deposit of $39.6 million and $59.4 million, primarily related to payments for inventory, were classified as accounts payable as of December 28, 2013 and December 29, 2012.

Accounts Receivable and Reserves

The carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate of the amounts that will not be collected. The reserve for accounts receivable is comprised of allowance for doubtful accounts and sales returns. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserve, including historical data, experience, customer types, credit worthiness and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect collectability.

Inventories and Reserves

Inventories consist primarily of finished goods and are valued at the lower of cost or market. Cost is determined by the first-in, first-out method for merchandise or actual cost for large equipment and high tech equipment. In accordance with our policy for inventory valuation, we consider many factors including the condition and salability of the inventory, historical sales, forecasted sales and market and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect the value of inventory.

Direct Shipping and Handling Costs

Freight and other direct shipping costs are included in cost of sales. Direct handling costs, which represent primarily direct compensation costs of employees who pick, pack and otherwise prepare, if necessary, merchandise for shipment to our customers are reflected in selling, general and administrative expenses. Direct shipping and handling costs were $69.1 million, $64.5 million and $62.5 million for the years ended December 28, 2013, December 29, 2012 and December 31, 2011.

Advertising and Promotional Costs

We generally expense advertising and promotional costs as incurred. Total advertising and promotional expenses were $12.2 million, $10.4 million and $13.1 million for the years ended December 28, 2013, December 29, 2012 and December 31, 2011. Additionally, advertising and promotional costs incurred in connection with direct marketing, including product catalogs and printed material, are deferred and amortized on a straight-line basis over the period which is benefited, generally not exceeding one year. As of December 28, 2013 and December 29, 2012, we had $3.9 million and $3.9 million of deferred direct marketing expenses included in other current assets.

Supplier Rebates

Supplier rebates are included as a reduction of cost of sales and are recognized over the period they are earned. The factors we consider in estimating supplier rebate accruals include forecasted inventory purchases and sales, in conjunction with supplier rebate contract terms, which generally provide for increasing rebates based on either increased purchase or sales volume.

Property and Equipment

Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is computed primarily under the straight-line method (see Note 2 - Property and Equipment, Net for estimated useful lives). Amortization of leasehold improvements is computed using the straight-line method over the lesser of the useful life of the assets or the lease term.

Capitalized software costs consist of costs to purchase and develop software. Costs incurred during the application development stage for software bought and further customized by outside suppliers for our use and software developed by a supplier for our proprietary use are capitalized. Costs incurred for our own personnel who are directly associated with software development are capitalized.

Income Taxes

We account for income taxes under an asset and liability approach that requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in tax laws or rates. The effect on deferred income tax assets and liabilities of a change in tax rates will be recognized as income or expense in the period that includes the enactment date. We file a consolidated U.S. federal income tax return with our 80% or greater owned U.S. subsidiaries.

Foreign Currency Translation and Transactions

The financial position and results of operations of our foreign subsidiaries are determined using local currency as the functional currency. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each year-end. Income statement accounts are translated at the average rate of exchange prevailing during the year. Translation adjustments arising from the use of differing exchange rates from period to period are included in Accumulated other comprehensive income in stockholders' equity. Gains and losses resulting from foreign currency transactions are included in earnings.

Risk Management and Derivative Financial Instruments

We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our objective is to manage the impact that foreign currency exchange rate fluctuations could have on recognized asset and liability fair values, earnings and cash flows. Our risk management policy requires that derivative contracts used as hedges be effective at reducing the risks associated with the exposure being hedged and be designated as a hedge at the inception of the contract. We do not enter into derivative instruments for speculative purposes. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans and certain forecasted inventory purchase commitments with foreign suppliers.

Our foreign currency forward agreements related to forecasted inventory purchase commitments are designated as cash flow hedges. Our foreign currency forward agreements related to foreign currency balance sheet exposure provide economic hedges but are not designated as hedges for accounting purposes.

For agreements not designated as hedges, changes in the value of the derivative, along with the transaction gain or loss on the hedged item, are recorded in earnings. For cash flow hedges, the effective portion of the changes in the fair value of the derivative, along with any gain or loss on the hedged item, is recorded as a component of Accumulated other comprehensive income in stockholders' equity and subsequently reclassified into earnings in the period(s) during which the hedged transaction affects earnings.

We classify the cash flows related to our hedging activities in the same category on our consolidated statements of cash flows as the cash flows related to the hedged item.

Acquisitions

The net assets of businesses purchased are recorded at their fair value at the acquisition date and our consolidated financial statements include their results of operations from that date. Any excess of acquisition consideration over the fair value of identifiable net assets acquired is recorded as goodwill. The major classes of assets and liabilities that we generally allocate purchase price to, excluding goodwill, include identifiable intangible assets (i.e., trademarks and trade names, customer relationships and lists and non-compete agreements), property, plant and equipment, deferred taxes and other current and long-term assets and liabilities. The estimated fair value of identifiable intangible assets is based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; customer retention rates; and estimated useful lives. Some prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. For the years ended December 28, 2013, December 29, 2012 and December 31, 2011, there were no material adjustments recorded in our consolidated statement of income relating to changes in estimated contingent purchase price liabilities.

Redeemable Noncontrolling Interests

Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Their interests in these subsidiaries are classified outside permanent equity on our consolidated balance sheets and are carried at the estimated redemption amounts. The redemption amounts have been estimated based on expected future earnings and cash flow and, if such earnings and cash flow are not achieved, the value of the redeemable noncontrolling interests might be impacted. Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are reflected at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.

Goodwill and Other Indefinite-Lived Intangible Assets

Goodwill and other indefinite-lived intangible assets (primarily trademarks) are not amortized, but are subject to impairment analysis at least once annually. Such impairment analyses for goodwill require a comparison of the fair value to the carrying value of reporting units. We regard our reporting units to be our operating segments: health care distribution (global dental, animal health and medical) and technology and value-added services.

We test goodwill for impairment under the provisions of Accounting Standards Update 2011-08, “Intangibles-Goodwill and Other (Topic 350): Testing Goodwill for Impairment” (“ASU 2011-08”), which allows us to use qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than their carrying values. The factors that we consider in developing our qualitative assessment included:

Macroeconomic conditions consisting of the overall sales growth of our business and the overall sales growth of each of our operating segments. We also consider our growth in market share in the markets in which we compete;
Credit markets and our ability to access debt facilities at favorable terms;
Key personnel and management expertise, as well as our growth strategies for the next several years; and
Our expectations of selling or disposing all, or a portion, of a reporting unit.

Goodwill was allocated to such reporting units, for the purposes of preparing our impairment analyses, based on a specific identification basis. Our impairment analysis for indefinite-lived intangibles consists of a comparison of the fair value to the carrying value of the assets. This comparison is made based on a review of historical, current and forecasted sales and gross profit levels, as well as a review of any factors that may indicate potential impairment. For certain indefinite-lived intangible assets, a present value technique, such as estimates of future cash flows, is utilized. We assessed the potential impairment of goodwill and other indefinite-lived intangible assets annually (at the beginning of our fourth quarter) and on an interim basis whenever events or changes in circumstances indicate that the carrying value may not be recoverable.

Some factors we consider important that could trigger an interim impairment review include:

significant underperformance relative to expected historical or projected future operating results;
significant changes in the manner of our use of acquired assets or the strategy for our overall business (e.g., decision to divest a business); or
significant negative industry or economic trends.

If we determine through the impairment review process that goodwill or other indefinite-lived intangible assets are impaired, we record an impairment charge in our consolidated statements of income.

Beginning with the first quarter of 2012, we changed our reporting units from dental, medical, animal health, international and technology to global dental, global animal health, global medical and global technology and value-added services.

These groups have been formed to provide distinct organizational focus for reaching and serving each practitioner segment with the benefits of a global perspective, as well as global product and service offerings and best practices.

In connection with this change in business groups, goodwill was reallocated to the new reporting units. Based upon this change, we felt it was necessary to perform a quantitative assessment, in addition to a qualitative assessment, of goodwill impairment as of the first day of the fourth quarter for the year ended December 29, 2012 in order to establish a new baseline calculation.

Based on a qualitative analysis, there were no events or circumstances from the date of that assessment through December 28, 2013 that impacted our analysis. For the years ended December 28, 2013, December 29, 2012 and December 31, 2011, the results of our goodwill impairment analysis did not result in any impairments.

Long-Lived Assets

Long-lived assets, other than goodwill and other indefinite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows derived from such assets.

Definite-lived intangible assets primarily consist of non-compete agreements, trademarks, trade names, customer lists, customer relationships and intellectual property. For long-lived assets used in operations, impairment losses are only recorded if the asset's carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. We measure the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.

Cost of Sales

The primary components of cost of sales include the cost of the product (net of purchase discounts, supplier chargebacks and rebates) and inbound and outbound freight charges. Costs related to purchasing, receiving, inspections, warehousing, internal inventory transfers and other costs of our distribution network are included in selling, general and administrative expenses along with other operating costs.

As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Total distribution network costs were $62.2 million, $59.5 million and $59.1 million for the years ended December 28, 2013, December 29, 2012 and December 31, 2011.

Comprehensive Income

Comprehensive income includes certain gains and losses that, under accounting principles generally accepted in the United States, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders' equity. Our comprehensive income is primarily comprised of net income, foreign currency translation adjustments, unrealized gains (losses) on hedging and investment activity and pension adjustments.

Property and Equipment, Net

12 Months Ended

Dec. 28, 2013

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

Note 2 – Property and Equipment, Net

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed primarily under the straight-line method over the estimated useful life. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the useful life of the assets or the lease term. Property and equipment, including related estimated useful lives, consisted of the following:

			December 28,		December 29,
			2013		2012
Land			$	19,981	$	13,531
Buildings and permanent improvements				112,514		112,979
Leasehold improvements				73,974		70,725
Machinery and warehouse equipment				71,129		68,432
Furniture, fixtures and other				118,806		102,569
Computer equipment and software				279,831		258,962
				676,235		627,198
Less accumulated depreciation				(400,347)		(353,740)
	Property and equipment, net		$	275,888	$	273,458



			Estimated Useful
			Lives (in years)
		Buildings and permanent improvements	40
		Machinery and warehouse equipment	5-10
		Furniture, fixtures and other	3-10
		Computer equipment and software	3-10

Property and equipment related depreciation expense for the years ended December 28, 2013, December 29, 2012 and December 31, 2011 was $52.9 million, $52.2 million and $53.0 million.

Goodwill and Other Intangibles, Net

12 Months Ended

Dec. 28, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangibles, Net

Note 3 – Goodwill and Other Intangibles, Net

The changes in the carrying amount of goodwill for the years ended December 28, 2013 and December 29, 2012 were as follows:

			Health Care Distribution		Technology and Value-Added Services		Total
Balance as of December 31, 2011			$	1,398,248	$	98,860	$	1,497,108
	Adjustments to goodwill:
		Acquisitions		30,765		61,788		92,553
		Foreign currency translation		9,909		1,476		11,385
Balance as of December 29, 2012				1,438,922		162,124		1,601,046
	Adjustments to goodwill:
		Acquisitions		22,055		6,369		28,424
		Foreign currency translation		4,361		1,174		5,535
Balance as of December 28, 2013			$	1,465,338	$	169,667	$	1,635,005

Other intangible assets consisted of the following:


	December 28, 2013						December 29, 2012
			Accumulated						Accumulated
	Cost		Amortization		Net		Cost		Amortization		Net
Non-compete agreements	$	44,162	$	(9,666)	$	34,496	$	47,351	$	(7,949)	$	39,402
Trademarks / trade names - definite lived		77,134		(27,794)		49,340		72,948		(18,474)		54,474
Trademarks / trade names - indefinite lived		3,717		-		3,717		3,681		-		3,681
Customer relationships and lists		478,852		(193,263)		285,589		504,387		(179,566)		324,821
Other		68,844		(24,853)		43,991		57,397		(17,593)		39,804
Total	$	672,709	$	(255,576)	$	417,133	$	685,764	$	(223,582)	$	462,182

Non-compete agreements represent amounts paid primarily to key employees and prior owners of acquired businesses, as well as certain sales persons, in exchange for placing restrictions on their ability to pose a competitive risk to us. Such amounts are amortized, on a straight-line basis over the respective non-compete period, which generally commences upon termination of employment or separation from us. The weighted-average non-compete period for agreements currently being amortized was approximately 5.6 years as of December 28, 2013.

Trademarks, trade names, customer lists and customer relationships were established through business acquisitions. Definite-lived trademarks and trade names are amortized on a straight-line basis over a weighted-average period of approximately 8.5 years as of December 28, 2013. Customer relationships and customer lists are definite-lived intangible assets that are amortized on a straight-line basis over a weighted-average period of approximately 11.0 years as of December 28, 2013.

Amortization expense related to definite-lived intangible assets for the years ended December 28, 2013, December 29, 2012 and December 31, 2011 was $69.2 million, $68.5 million and $58.8 million. The annual amortization expense expected for the years 2014 through 2018 is $62.6 million, $57.3 million, $51.6 million, $47.9 million and $42.4 million.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Investments and Other

12 Months Ended

Dec. 28, 2013

Investments And Other [Abstract]

Investments and Other

Note 4 – Investments and Other

Investments and other consisted of the following:

		December 28,		December 29,
		2013		2012
Investment in unconsolidated affiliates		$	205,556	$	191,075
Non-current deferred foreign, state and local income taxes			48,470		37,737
Notes receivable (1)			10,836		9,851
Auction rate securities, net of temporary impairment			2,654		2,816
Distribution rights and exclusivity agreements, net of amortization			3,321		4,030
Security deposits			3,341		3,291
Debt issuance costs, net of amortization			2,011		7,207
Acquisition related indemnification			13,880		14,168
Acquisition related loan receivable (2)			145,000		-
Other long-term assets			26,876		22,759
	Total	$	461,945	$	292,934


(1)	Long-term notes receivable carry interest rates ranging from 2.17% to 12.0% and are due in varying installments through
	December 31, 2020.

(2)	See Note 9 - Business Acquisitions, Divestiture and Other Transaction for additional details of the loan receivable from
	BioHorizons, Inc.

Amortization expense related to other long-term assets for the years ended December 28, 2013, December 29, 2012 and December 31, 2011 was $6.0 million, $4.6 million and $4.0 million.

Debt

12 Months Ended

Dec. 28, 2013

Debt Disclosure [Abstract]

Debt

Note 5 – Debt

Credit Facilities

On September 12, 2012, we entered into a new $500 million revolving credit agreement (the “Credit Agreement”) with a $200 million expansion feature, which expires on September 12, 2017. This credit facility replaced our then existing $400 million revolving credit facility with a $100 million expansion feature, which would have expired on September 5, 2013. There were no borrowings outstanding under this revolving credit facility as of December 28, 2013. The interest rate is based on USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. The Credit Agreement provides, among other things, that we are required to maintain certain interest coverage and maximum leverage ratios, and contains customary representations, warranties and affirmative covenants. The Credit Agreement also contains customary negative covenants, subject to negotiated exceptions on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of December 28, 2013, there were $10.1 million of letters of credit provided to third parties under the credit facility.

As of December 28, 2013, we had various other short-term bank credit lines available, of which approximately $29.5 million was outstanding. At December 28, 2013, borrowings under all of our credit lines had a weighted average interest rate of 2.73%.

Private Placement Facilities

On August 10, 2010, we entered into $400 million private placement facilities with two insurance companies. On April 30, 2012, we increased our available credit facilities by $375 million by entering into a new agreement with one insurance company and amending our existing agreements with two insurance companies. These facilities are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time during a three year issuance period, through April 26, 2015. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates.

The components of our private placement facility borrowings as of December 28, 2013 are presented in the following table:


	Amount of
	Borrowing		Borrowing
Date of Borrowing	Outstanding		Rate		Due Date
September 2, 2010	$	100,000	3.79	%	September 2, 2020
January 20, 2012		50,000	3.45		January 20, 2024
January 20, 2012 (1)		50,000	3.09		January 20, 2022
December 24, 2012		50,000	3.00		December 24, 2024
	$	250,000


(1) Annual repayments of approximately $7.1 million for this borrowing will commence on January 20, 2016.

Henry Schein Animal Health

During the first quarter of 2013, we repaid the then outstanding debt related to the Henry Schein Animal Health (“HSAH”), formerly Butler Schein Animal Health, transaction using our existing Credit Agreement. As part of this transaction, we recorded a one-time interest expense charge of $6.2 million related to the accelerated amortization of deferred financing costs.

U.S. Trade Accounts Receivable Securitization

On April 17, 2013, we entered into a facility agreement of up to $300 million with a bank, as agent, based on the securitization of our U.S. trade accounts receivable. The new facility allowed us to replace public debt (approximately $220 million), which had a higher interest rate at HSAH during February 2013 and provided funding for working capital and general corporate purposes. The financing was structured as an asset-backed securitization program with pricing committed for up to three years. The borrowings outstanding under this securitization facility were $160 million as of December 28, 2013. At December 28, 2013, the interest rate on borrowings under this facility is based on the average asset-backed commercial paper rate of 21 basis points plus 75 basis points, for a combined rate of 0.96%.

We are required to pay a commitment fee of 30 basis points on the daily balance of the unused portion of the facility if usage is greater than or equal to 50% of the facility limit or a commitment fee of 35 basis points on the daily balance of the unused portion of the facility if usage is less than 50% of the facility limit.

Borrowings under this facility are presented as a component of Long-term debt within our consolidated balance sheet.

Long-term debt

Long-term debt consisted of the following:

		December 28,		December 29,
		2013		2012
Private placement facilities		$	250,000	$	250,000
U.S. trade accounts receivable securitization			160,000		-
Notes payable to banks at a weighted-average interest rate of 8.23%			73		11,352
Butler Schein Animal Health Supply notes payable to banks (net of discount of
	$0 million and $0.7 million)		-		220,439
Various collateralized and uncollateralized loans payable with interest,
	in varying installments through 2018 at interest rates ranging
	from 2.4% to 5.41%		44,091		21,178
Capital lease obligations (see Note 17)			1,510		3,144
Total			455,674		506,113
Less current maturities			(5,441)		(17,992)
	Total long-term debt	$	450,233	$	488,121

As of December 28, 2013, the aggregate amounts of long-term debt, including capital lease obligations, maturing in each of the next five years and thereafter are as follows:

2014		$	5,441
2015			3,223
2016			170,336
2017			17,801
2018			30,302
Thereafter			228,571
	Total	$	455,674

Redeemable Noncontrolling Interests

12 Months Ended

Dec. 28, 2013

Temporary Equity Disclosure [Abstract]

Redeemable Noncontrolling Interests

Note 6 – Redeemable Noncontrolling Interests

Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification (“ASC”) Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the Redeemable noncontrolling interests for the years ended December 28, 2013, December 29, 2012 and December 31, 2011 are presented in the following table:

		December 28,		December 29,		December 31,
		2013		2012		2011
Balance, beginning of period		$	435,175	$	402,050	$	304,140
Decrease in redeemable noncontrolling interests due to
	redemptions		(9,028)		(23,637)		(160,254)
Increase in redeemable noncontrolling interests due to
	business acquisitions		11,542		30,935		13,618
Net income attributable to redeemable noncontrolling interests			39,430		34,803		36,514
Dividends declared			(19,965)		(21,013)		(15,212)
Effect of foreign currency translation gain (loss) attributable to
	redeemable noncontrolling interests		(654)		904		(889)
Change in fair value of redeemable securities			41,039		53,769		224,133
Other adjustment to redeemable noncontrolling interests			-		(42,636)		-
Balance, end of period		$	497,539	$	435,175	$	402,050

Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are adjusted at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.

Comprehensive Income

12 Months Ended

Dec. 28, 2013

Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]

Comprehensive Income

Note 7 – Comprehensive Income

Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders' equity. Our comprehensive income is primarily comprised of net income, foreign currency translation gain (loss), unrealized gain (loss) on foreign currency hedging activities, unrealized investment gain (loss) and pension adjustment gain (loss).

The following table summarizes our Accumulated other comprehensive income, net of applicable taxes as of:

		December 28,		December 29,		December 31,
		2013		2012		2011
Attributable to Redeemable noncontrolling interests:
	Foreign currency translation adjustment	$	(1,503)	$	(849)	$	(1,753)

Attributable to Henry Schein, Inc.:
Foreign currency translation gain		$	82,288	$	72,160	$	39,717
Unrealized gain (loss) from foreign currency hedging activities			1,282		1,187		(1,678)
Unrealized investment loss			(515)		(415)		(829)
Pension adjustment loss			(15,206)		(20,077)		(14,626)
	Accumulated other comprehensive income	$	67,849	$	52,855	$	22,584

Total Accumulated other comprehensive income		$	66,346	$	52,006	$	20,831

The following table summarizes the components of comprehensive income, net of applicable taxes as follows:

	December 28,		December 29,		December 31,
	2013		2012		2011
Net income	$	471,462	$	423,388	$	404,656

Foreign currency translation gain (loss)		9,474		33,347		(2,310)
Tax effect		-		-		-
Foreign currency translation gain (loss)		9,474		33,347		(2,310)

Unrealized gain (loss) from foreign currency hedging activities		69		3,519		(712)
Tax effect		26		(654)		94
Unrealized gain (loss) from foreign currency hedging activities		95		2,865		(618)

Unrealized investment gain (loss)		(166)		724		562
Tax effect		66		(310)		(215)
Unrealized investment gain (loss)		(100)		414		347

Pension adjustment gain (loss)		6,207		(7,638)		(7,772)
Tax effect		(1,336)		2,187		1,534
Pension adjustment gain (loss)		4,871		(5,451)		(6,238)

Comprehensive income	$	485,802	$	454,563	$	395,837

The following table summarizes our total comprehensive income, net of applicable taxes as follows:

		December 28,		December 29,		December 31,
		2013		2012		2011
Comprehensive income attributable to
	Henry Schein, Inc.	$	446,548	$	418,347	$	359,731
Comprehensive income attributable to
	noncontrolling interests		478		509		481
Comprehensive income attributable to
	Redeemable noncontrolling interests		38,776		35,707		35,625
Comprehensive income		$	485,802	$	454,563	$	395,837

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Fair Value Measurements

12 Months Ended

Dec. 28, 2013

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 8 – Fair Value Measurements

ASC Topic 820 “Fair Value Measurements and Disclosures” (“ASC Topic 820”) provides a framework for measuring fair value in generally accepted accounting principles.

ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).

The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows:

• Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.

• Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

• Level 3— Inputs that are unobservable for the asset or liability.

The following section describes the valuation methodologies that we used to measure different financial instruments at fair value.

Investments and notes receivable

There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable; however, we believe the carrying amounts are a reasonable estimate of fair value.

Debt

The fair value of our debt as of December 28, 2013 and December 29, 2012 was estimated at $485.2 million and $533.3 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, prepayment and make-whole provisions, liquidity levels in the private placement market, variability in pricing from multiple lenders and term of debt.

Derivative contracts

Derivative contracts are valued using quoted market prices and significant other observable and unobservable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to intercompany loans and certain forecasted inventory purchase commitments with suppliers.

The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy.

Redeemable noncontrolling interests

Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value based on third-party valuations. The primary factor affecting the future value of redeemable noncontrolling interests is expected earnings and, if such earnings are not achieved, the value of the redeemable noncontrolling interests might be impacted. The noncontrolling interests subject to put options are adjusted to their estimated redemption amounts each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share. The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy. The details of the changes in Redeemable noncontrolling interests are presented in Note 6.

The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 28, 2013 and December 29, 2012:

			December 28, 2013
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts			-		1,235		-		1,235
		Total assets	$	-	$	1,235	$	-	$	1,235

Liabilities:
	Derivative contracts		$	-	$	1,142	$	-	$	1,142
		Total liabilities	$	-	$	1,142	$	-	$	1,142

Redeemable noncontrolling interests			$	-	$	-	$	497,539	$	497,539


			December 29, 2012
				Level 1		Level 2		Level 3		Total

Assets:
	Available-for-sale securities		$	-	$	-	$	2,816	$	2,816
	Derivative contracts			-		710		-		710
		Total assets	$	-	$	710	$	2,816	$	3,526

Liabilities:
	Derivative contracts		$	-	$	1,159	$	-	$	1,159
		Total liabilities	$	-	$	1,159	$	-	$	1,159

Redeemable noncontrolling interests			$	-	$	-	$	435,175	$	435,175

Business Acquisitions, Divestiture and Other Transaction

12 Months Ended

Dec. 28, 2013

Business Acquisitions, Divestiture And Other Transactions [Abstract]

Business Acquisitions, Divestiture and Other Transaction

Note 9 – Business Acquisitions, Divestiture and Other Transaction

Acquisitions

The operating results of all acquisitions are reflected in our financial statements from their respective acquisition dates.

We completed certain acquisitions during the year ended December 28, 2013, which were immaterial to our financial statements individually and in the aggregate and resulted in the recording of approximately $14.7 million of initial goodwill through preliminary purchase price allocations. Total acquisition transaction costs incurred in the year ended December 28, 2013 were immaterial to our financial results.

We completed certain acquisitions during the year ended December 29, 2012, which were immaterial to our financial statements individually and in the aggregate and resulted in the recording of approximately $128.0 million of initial goodwill through preliminary purchase price allocations.

On December 31, 2010, we acquired 100% of the outstanding shares of Provet Holdings Limited (ASX: PVT), an Australasian distributor of veterinary products with sales in its 2010 fiscal year of approximately $278 million, for approximately $91 million, in a cash-for-stock exchange. As a result of the acquisition, we recorded $27.0 million of goodwill.

In addition to the Provet Holdings Limited acquisition, we completed other acquisitions during the year ended December 31, 2011, the operating results of which are reflected in our financial statements from their respective acquisition dates. These other acquisitions individually and in the aggregate had an immaterial impact on our reported operating results and resulted in the recording of approximately $38.8 million of initial goodwill through preliminary purchase price allocations.

Subsequent Acquisitions

On December 30, 2013, we completed the acquisition of an approximately 60% equity investment in BioHorizons, Inc., a U.S.-based manufacturer of advanced dental implants with annual revenues of approximately $115 million. Prior to completion of the acquisition, we funded BioHorizons, Inc. $145 million, which is recorded as a long-term loan included in Investments and Other within our consolidated balance sheet at December 28, 2013. This long-term loan was subsequently recorded as an intercompany loan upon completion of the acquisition and will be eliminated from our consolidated balance sheet in future reporting periods.

On January 6, 2014, we announced that we will acquire 100% ownership of five businesses in three European countries from Arseus NV. The businesses combine for annual sales of approximately $97 million and include a dental practice management software company in France and distributors of dental products in France, the Netherlands and Belgium. This transaction was completed during the first quarter of 2014.

Divestiture of an Equity Affiliate

On July 10, 2013, we divested our investment in a dental wholesale distributor in the Middle East that had primarily served as an importer that distributed products largely to other distributors. The divestiture resulted in a one-time loss, which is recorded in a separate line item, “Loss on sale of equity investment” within our consolidated statements of income and within the cash flows from operating activities section of our consolidated statements of cash flows, of $12.5 million, or $0.14 per diluted share, in the third quarter of 2013. Pursuant to the terms of this divestiture, we made cash payments, which are recorded in a separate line item, “Payments related to sale of equity investment”, within the cash flows from investing activities section of our consolidated statements of cash flows, to this distributor in the aggregate amount of $13.4 million, which it was required to use to reduce its debt, pay certain trade payables and provide working capital. The investment in this distributor had been fully impaired as of the end of 2012. There is no tax benefit related to the loss on this divestiture.

Loan and Investment Agreement

On December 12, 2008, we converted $10.4 million of loan receivables and related accrued interest into an equity interest of 15.33% in D4D Technologies, LLC (“D4D”). Since that date, we have accounted for our equity interest in D4D under the equity method of accounting.

On August 3, 2009, we entered into an amendment whereby we paid certain of D4D's members approximately $8.0 million. Such payment is included in Investments and other in our consolidated financial statements and is being amortized over a period of 15 years. On September 30, 2013, we purchased additional equity in D4D, increasing our ownership to 21.4%.

Plans of Restructuring

12 Months Ended

Dec. 28, 2013

Restructuring and Related Activities [Abstract]

Plans of Restructuring

Note 10 – Plans of Restructuring

During the year ended December 29, 2012, we incurred restructuring costs of approximately $15.2 million (approximately $10.5 million after taxes) consisting of employee severance pay and benefits related to the elimination of approximately 200 positions; facility closing costs, representing primarily lease terminations and property and equipment write-off costs; and outside professional and consulting fees directly related to the restructuring plan. This restructuring program is complete and we do not expect any additional costs from this program.

The costs associated with this restructuring are included in a separate line item, “Restructuring costs” within our consolidated statements of income.

The following table shows the amounts expensed and paid for restructuring costs that were incurred during our 2013, 2012 and 2011 fiscal years and the remaining accrued balance of restructuring costs as of December 28, 2013, which is included in Accrued expenses: Other and Other liabilities within our consolidated balance sheet:


			Facility
	Severance		Closing
	Costs		Costs		Total
Balance, December 25, 2010		1,992		2,351		4,343
Provision		-		-		-
Payments and other adjustments		(1,423)		(1,800)		(3,223)
Balance, December 31, 2011		569		551		1,120
Provision		12,841		2,351		15,192
Payments and other adjustments		(11,584)		(1,671)		(13,255)
Balance, December 29, 2012		1,826		1,231		3,057
Provision		-		-		-
Payments and other adjustments		(1,599)		(747)		(2,346)
Balance, December 28, 2013	$	227	$	484	$	711

The following table shows, by reportable segment, the amounts expensed and paid for restructuring costs that were incurred during our 2013, 2012 and 2011 fiscal years and the remaining accrued balance of restructuring costs as of December 28, 2013:

			Technology and
	Health Care		Value-Added
	Distribution		Services		Total
Balance, December 25, 2010		4,343		-		4,343
Provision		-		-		-
Payments and other adjustments		(3,223)		-		(3,223)
Balance, December 31, 2011		1,120		-		1,120
Provision		14,981		211		15,192
Payments and other adjustments		(13,058)		(197)		(13,255)
Balance, December 29, 2012		3,043		14		3,057
Provision		-		-		-
Payments and other adjustments		(2,332)		(14)		(2,346)
Balance, December 28, 2013	$	711	$	-	$	711

Earnings Per Share

12 Months Ended

Dec. 28, 2013

Earnings Per Share [Abstract]

Earnings Per Share

Note 11 – Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted-average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested restricted stock and restricted stock units and upon exercise of stock options, using the treasury stock method in periods in which they have a dilutive effect.

A reconciliation of shares used in calculating earnings per basic and diluted share follows:

		Years Ended
		December 28,	December 29,	December 31,
		2013	2012	2011
Basic		85,926	87,499	90,120
Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	1,696	2,324	2,500
	Diluted	87,622	89,823	92,620

Weighted-average options to purchase 8 shares of common stock at an exercise price of $69.45 per share that were outstanding during the year ended December 31, 2011 were excluded from the computation of diluted earnings per share because the options' exercise price exceeded the average market price of our common stock during the year, thereby causing the effect of such options to be anti-dilutive.

Income Taxes

12 Months Ended

Dec. 28, 2013

Income Tax Disclosure [Abstract]

Income Taxes

Note 12 – Income Taxes

Income before taxes, equity in earnings of affiliates and loss on sale of equity investment was as follows:

		Years ended
		December 28,		December 29,		December 31,
		2013		2012		2011
Domestic		$	517,950	$	466,457	$	403,171
Foreign			146,744		137,731		166,136
	Total	$	664,694	$	604,188	$	569,307

The provisions for income taxes were as follows:

				Years ended
				December 28,		December 29,		December 31,
				2013		2012		2011
Current income tax expense:
	U.S. Federal			$	139,253	$	121,591	$	125,148
	State and local				27,272		23,279		30,423
	Foreign				35,880		32,916		43,960
		Total current			202,405		177,786		199,531

Deferred income tax expense (benefit):
	U.S. Federal				10,325		9,242		(12,466)
	State and local				(4,531)		946		(1,782)
	Foreign				(17,308)		(116)		(5,071)
		Total deferred			(11,514)		10,072		(19,319)
			Total provision	$	190,891	$	187,858	$	180,212

The tax effects of temporary differences that give rise to our deferred income tax asset (liability) were as follows:

			Years Ended
			December 28,		December 29,
			2013		2012
Current deferred income tax assets:
	Inventory, premium coupon redemptions and accounts receivable
		valuation allowances	$	31,016	$	27,820
	Uniform capitalization adjustments to inventories			7,318		9,944
	Other current assets			21,351		21,035
	Current deferred income tax asset (1)			59,685		58,799

Non-current deferred income tax asset (liability):
	Property and equipment			(5,571)		(5,661)
	Stock-based compensation			35,995		42,875
	Other non-current liabilities			(211,180)		(215,562)
	Net operating losses of domestic subsidiaries			693		2,768
	Net operating losses of foreign subsidiaries			45,254		47,101
		Total non-current deferred tax liability		(134,809)		(128,479)
		Valuation allowance for non-current deferred tax assets (2)		(16,285)		(30,598)
	Net non-current deferred tax liability (1)			(151,094)		(159,077)
Net deferred income tax liability			$	(91,409)	$	(100,278)


(1)	Certain deferred tax amounts do not have a right of offset and are therefore reflected on a gross basis in current assets
	and non-current liabilities in our consolidated balance sheets.

(2)	Primarily relates to operating losses of acquired foreign subsidiaries, the benefits of which are uncertain. Any future reductions
	of such valuation allowances will be reflected as a reduction of income tax expense in accordance with the provisions of
	ASC Topic 805, “Business Combinations.”

The assessment of the amount of value assigned to our deferred tax assets under the applicable accounting rules is judgmental. We are required to consider all available positive and negative evidence in evaluating the likelihood that we will be able to realize the benefit of our deferred tax assets in the future. Such evidence includes scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and the results of recent operations. Since this evaluation requires consideration of events that may occur some years into the future, there is an element of judgment involved. Realization of our deferred tax assets is dependent on generating sufficient taxable income in future periods. We believe that it is more likely than not that future taxable income will be sufficient to allow us to recover substantially all of the value assigned to our deferred tax assets. However, if future events cause us to conclude that it is not more likely than not that we will be able to recover all of the value assigned to our deferred tax assets, we will be required to adjust our valuation allowance accordingly.

As of December 28, 2013, we have state net operating loss carryforwards of $6.9 million relating to our domestic subsidiaries, which can be utilized against future state income through December 31, 2029. As of December 28, 2013, we have foreign net operating loss carryforwards of $11.7 million, which can be utilized against future foreign income through December 31, 2019. Additionally, as of December 28, 2013, there were foreign net operating loss carryforwards of $153.1 million that have an indefinite life.

The tax provisions differ from the amount computed using the federal statutory income tax rate as follows:

		Years ended
		December 28,		December 29,		December 31,
		2013		2012		2011
Income tax provision at federal statutory rate		$	232,644	$	211,466	$	199,256
State income tax provision, net of federal income tax effect			20,134		21,665		18,035
Foreign income tax benefit			(19,635)		(17,979)		(20,169)
Valuation allowance			(14,026)		1,502		442
Interest expense related to loans			(23,723)		(21,018)		(14,394)
Other			(4,503)		(7,778)		(2,958)
	Total income tax provision	$	190,891	$	187,858	$	180,212

For the year ended December 28, 2013, our effective tax rate was 28.7% compared to 31.1% for the prior year period. During the third quarter of 2013, we concluded that it is more likely than not that certain deferred tax assets related to tax loss carryforwards originating outside the United States, which had been previously reserved, will be realized. As a result, our provision for income taxes includes a $13.4 million reduction of the valuation allowance which is based on an estimate of future taxable income available to be offset by the tax loss carryforwards.

Absent the effects of the reduction of this valuation allowance in the third quarter of 2013, our effective tax rate for the year ended December 28, 2013 would have been 30.7% as compared to our actual effective tax rate of 28.7%. The remaining difference between our effective tax rates and the federal statutory tax rates for both periods primarily relates to state and foreign income taxes and interest expense.

Provision has not been made for U.S. or additional foreign taxes on undistributed earnings of foreign subsidiaries, which have been, and will continue to be reinvested. These earnings could become subject to additional tax if they were remitted as dividends, if foreign earnings were loaned to us or a U.S. affiliate, or if we should sell, transfer or dispose of our stock in the foreign subsidiaries. It is not practicable to determine the amount of additional tax, if any, that might be payable on the foreign earnings because if we were to repatriate these earnings, we believe there would be various methods available to us, each with different U.S. tax consequences. As of December 28, 2013, the cumulative amount of reinvested earnings was approximately $694.2 million.

ASC Topic 740 clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with other provisions contained within this guidance. This topic prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by the taxing authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate audit settlement. In the normal course of business, our tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax and interest assessments by these taxing authorities for uncertain tax positions taken in respect to certain tax matters.

The total amount of unrecognized tax benefits as of December 28, 2013 was approximately $54.1 million, of which $40.3 million would affect the effective tax rate if recognized. It is expected that the amount of unrecognized tax benefits will change in the next 12 months; however, we do not expect the change to have a material impact on our consolidated financial statements.

The total amounts of interest and penalties, which are classified as a component of the provision for income taxes, were approximately $10.9 million and $0, respectively, as of December 28, 2013.

The tax years subject to examination by major tax jurisdictions include the years 2009 and forward by the U.S. Internal Revenue Service, the years 2000 and forward for certain states and the years 2005 and forward for certain foreign jurisdictions.

The following table provides a reconciliation of unrecognized tax benefits excluding the effects of deferred taxes, interest and penalties:

	December 28,		December 29,
	2013		2012
Balance, beginning of period	$	32,700	$	19,200
Additions based on current year tax positions		6,000		4,900
Additions based on prior year tax positions		9,600		11,200
Reductions based on prior year tax positions		(1,100)		(600)
Reductions resulting from settlements with taxing authorities		(800)		(1,300)
Reductions resulting from lapse in statutes of limitations		(3,200)		(700)
Balance, end of period	$	43,200	$	32,700

Concentrations of Risk

12 Months Ended

Dec. 28, 2013

Risks and Uncertainties [Abstract]

Concentrations of Risk

Note 13 – Concentrations of Risk

Certain financial instruments potentially subject us to concentrations of credit risk. These financial instruments consist primarily of cash equivalents, trade receivables, long-term investments, notes receivable and derivative instruments. In all cases, our maximum exposure to loss from credit risk equals the gross fair value of the financial instruments. We continuously assess the need for reserves for such losses, which have been within our expectations. We do not require collateral or other security to support financial instruments subject to credit risk, except for long-term notes receivable.

We limit our credit risk with respect to our cash equivalents, short-term and long-term investments and derivative instruments, by monitoring the credit worthiness of the financial institutions who are the counter-parties to such financial instruments. As a risk management policy, we limit the amount of credit exposure by diversifying and utilizing numerous investment grade counter-parties.

With respect to our trade receivables, our credit risk is somewhat limited due to a relatively large customer base and its dispersion across different types of health care professionals and geographic areas. No single customer accounted for more than 0.8% of our net sales in 2013. With respect to our sources of supply, our top 10 health care distribution suppliers and our single largest supplier accounted for approximately 37% and 8%, respectively, of our aggregate purchases in 2013.

Our long-term notes receivable primarily represent strategic financing arrangements with certain industry affiliates and amounts owed to us from sales of certain businesses. Generally, these notes are secured by certain assets of the counter-party; however, in most cases our security is subordinate to other commercial financial institutions. While we have exposure to credit loss in the event of non-performance by these counter-parties, we conduct ongoing assessments of their financial and operational performance.

Derivatives and Hedging Activities

12 Months Ended

Dec. 28, 2013

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivatives and Hedging Activities

Note 14 – Derivatives and Hedging Activities

We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S. dollar and each other, and changes to the credit markets. We attempt to minimize these risks by primarily using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our investments, maintaining a strong balance sheet and having multiple sources of capital.

Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Our hedging activities have historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by ASC Topic 815 have been omitted.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41635-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624181-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Segment Data

12 Months Ended

Dec. 28, 2013

Segment Reporting [Abstract]

Segment Data

Note 15 – Segment and Geographic Data

We conduct our business through two reportable segments: health care distribution and technology and value-added services. These segments offer different products and services to the same customer base. The health care distribution reportable segment aggregates our global dental, animal health and medical operating segments. This segment consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Our global dental group serves office-based dental practitioners, dental laboratories, schools and other institutions. Our global animal health group serves animal health practices and clinics. Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other alternate-care settings and other institutions. Our global dental, animal health and medical groups serve practitioners in 25 countries worldwide.

Our global technology and value-added services group provides software, technology and other value-added services to health care practitioners. Our technology group offerings include practice management software systems for dental and medical practitioners and animal health clinics. Our value-added practice solutions include financial services on a non-recourse basis, e-services and continuing education services for practitioners.

Beginning with the first quarter of 2012, we have reported net sales and prior-year sales comparisons for each of our global dental, animal health and medical and global technology and value-added services business groups.

This sales reporting is consistent with our global business groups as realigned in 2012. These groups have been formed to provide distinct organizational focus for reaching and serving each practitioner segment with the benefits of a global perspective, as well as global product and service offerings and best practices.

We will continue to report financial results for our health care distribution and technology and value-added services reportable segments. The health care distribution segment comprises three global operating segments (dental, animal health and medical) and the technology and value-added services segment remains unchanged.

In connection with this change in business groups, goodwill was reallocated to the new reporting units. We reviewed the newly allocated goodwill and determined that there was no impairment.

The following tables present information about our reportable and operating segments:

				Years Ended
				December 28,		December 29,		December 31,
				2013		2012		2011
Net Sales:
	Health care distribution (1):
		Dental		$	4,997,972	$	4,774,482	$	4,764,898
		Animal health			2,599,461		2,321,151		2,010,270
		Medical			1,643,167		1,560,921		1,504,454
			Total health care distribution		9,240,600		8,656,554		8,279,622
	Technology and value-added services (2)				320,047		283,413		250,620
		Total		$	9,560,647	$	8,939,967	$	8,530,242


(1)	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
	generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(2)	Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
	and financial and other services, including e-services and continuing education services for practitioners.

			Years ended
			December 28,		December 29,		December 31,
			2013		2012		2011
Operating Income:
	Health care distribution		$	590,664	$	541,667	$	512,094
	Technology and value-added services			86,390		77,294		70,055
		Total	$	677,054	$	618,961	$	582,149

Income before taxes and equity in earnings of affiliates
	Health care distribution		$	581,759	$	529,236	$	501,266
	Technology and value-added services			82,935		74,952		68,041
		Total	$	664,694	$	604,188	$	569,307

Depreciation and Amortization:
	Health care distribution		$	113,670	$	113,688	$	106,485
	Technology and value-added services			14,365		11,634		9,411
		Total	$	128,035	$	125,322	$	115,896

Income Tax Expense:
	Health care distribution		$	165,869	$	165,346	$	157,391
	Technology and value-added services			25,022		22,512		22,821
		Total	$	190,891	$	187,858	$	180,212

Interest Income:
	Health care distribution		$	12,816	$	13,293	$	15,531
	Technology and value-added services			37		101		62
		Total	$	12,853	$	13,394	$	15,593

Interest Expense:
	Health care distribution		$	27,375	$	30,790	$	30,350
	Technology and value-added services			163		112		27
		Total	$	27,538	$	30,902	$	30,377

Purchases of Fixed Assets:
	Health care distribution		$	57,364	$	47,057	$	42,751
	Technology and value-added services			2,851		4,180		2,425
		Total	$	60,215	$	51,237	$	45,176

			As of
			December 28,		December 29,		December 31,
			2013		2012		2011
Total Assets:
	Health care distribution		$	5,277,354	$	5,001,188	$	4,542,331
	Technology and value-added services			347,282		332,809		197,813
		Total	$	5,624,636	$	5,333,997	$	4,740,144

The following table presents information about our operations by geographic area as of and for the three years ended December 28, 2013. Net sales by geographic area are based on the respective locations of our subsidiaries. No country, except for the United States, generated net sales greater than 10% of consolidated net sales. There were no material amounts of sales or transfers among geographic areas and there were no material amounts of export sales.

		2013				2012				2011
		Net Sales		Long-Lived Assets		Net Sales		Long-Lived Assets		Net Sales		Long-Lived Assets
United States		$	5,813,512	$	1,272,683	$	5,496,969	$	1,313,866	$	5,212,861	$	1,279,913
Other			3,747,135		1,055,343		3,442,998		1,022,820		3,317,381		888,895
	Consolidated total	$	9,560,647	$	2,328,026	$	8,939,967	$	2,336,686	$	8,530,242	$	2,168,808

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Employee Benefit Plans

12 Months Ended

Dec. 28, 2013

Employee Benefit Plans

Note 16 – Employee Benefit Plans

Stock-based Compensation

Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of $35.5 million ($24.6 million after-tax), $37.3 million ($25.7 million after-tax) and $36.9 million ($25.2 million after-tax) for the years ended December 28, 2013, December 29, 2012 and December 31, 2011.

Our accompanying consolidated statements of cash flows present our stock-based compensation expense as an adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the accompanying consolidated statements of cash flows, we presented $8.1 million, $17.8 million and $8.8 million of benefits associated with tax deductions in excess of recognized compensation as a cash inflow from financing activities for the years ended December 28, 2013, December 29, 2012 and December 31, 2011.

Stock-based compensation represents the cost related to stock-based awards granted to employees and non-employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis over the requisite service period. Our stock-based compensation expense is reflected in selling, general and administrative expenses in our consolidated statements of income.

Stock-based awards are provided to certain employees and non-employee directors under the terms of our 2013 Stock Incentive Plan, as amended, and our 1996 Non-Employee Director Stock Incentive Plan, as amended (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors. Prior to March 2009, awards under the Plans principally included a combination of at-the-money stock options and restricted stock (including restricted stock units). Since March 2009, equity-based awards have been granted solely in the form of restricted stock and restricted stock units, with the exception of stock options for certain pre-existing contractual obligations. As of December 28, 2013, there were 31,229 shares authorized and 6,583 shares available to be granted under the 2013 Stock Incentive Plan and 800 shares authorized and 93 shares available to be granted under the 1996 Non-Employee Director Stock Incentive Plan.

Stock options are awards that allow the recipient to purchase shares of our common stock at a fixed price. Stock options are granted at an exercise price equal to our closing stock price on the date of grant. These awards, which generally vest 25% per year based on the recipient's continued service subject to the terms and conditions of the Plans, are fully vested four years from the grant date and have a contractual term of ten years from the grant date. Additionally, recipients may not sell any shares that they acquire through exercising their stock options until the third anniversary of the date of grant of such options. We estimated the fair value of stock options using the Black-Scholes valuation model.

Grants of restricted stock are common stock awards granted to recipients with specified vesting provisions. We issue restricted stock that vests solely based on the recipient's continued service over time (primarily four-year cliff vesting) and restricted stock that vests based on our achieving specified performance measurements and the recipient's continued service over time (primarily three-year cliff vesting).

With respect to time-based restricted stock, we estimate the fair value on the date of grant based on our closing stock price. With respect to performance-based restricted stock, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a three-year period as determined by the Compensation Committee of the Board of Directors. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based restricted stock based on our closing stock price at time of grant.

The Plans provide for adjustments to the performance-based restricted stock targets for significant events such as acquisitions, divestitures, new business ventures and share repurchases. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans.

Restricted stock units are awards that we grant to certain employees that entitle the recipient to shares of common stock upon vesting. We grant restricted stock units with the same time-based and performance-based vesting that we use for restricted stock. The fair value of restricted stock units is determined on the date of grant, based on our closing stock price.

We record deferred income tax assets for awards that will result in future deductions on our income tax returns based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Differences between the deferred income tax assets recognized for financial reporting purposes and the actual tax deduction reported on our income tax return are recorded in additional paid-in capital (if the tax deduction exceeds the deferred income tax asset) or in earnings (if the deferred income tax asset exceeds the tax deduction and no additional paid-in capital exists from previous awards).

Stock-based compensation grants for the three years ended December 28, 2013 primarily consisted of restricted stock and restricted stock unit grants. Certain stock-based compensation granted may require us to settle in the form of a cash payment. During the year ended December 28, 2013, we recorded a liability of $0.5 million relating to the grant date fair value of stock-based compensation to be settled in cash, as well as an expense of $0.6 million relating to the change in the fair value of these grants. The weighted-average grant date fair value of stock-based awards granted before forfeitures was $89.97, $73.42 and $68.25 per share during the years ended December 28, 2013, December 29, 2012 and December 31, 2011.

Total unrecognized compensation cost related to non-vested awards as of December 28, 2013 was $69.8 million, which is expected to be recognized over a weighted-average period of approximately 2.0 years.

A summary of the stock option activity under the Plans is presented below:

	Years Ended
	December 28,			December 29,			December 31,
	2013			2012			2011

		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at beginning of year	2,138	$	48.61	4,059	$	44.53	5,012	$	43.05
Granted	-		-	-		-	10		69.45
Exercised	(815)		43.86	(1,890)		40.06	(942)		36.84
Forfeited	-		-	(31)		36.02	(21)		48.35
Outstanding at end of year	1,323	$	51.53	2,138	$	48.61	4,059	$	44.53

Options exercisable at end of year	1,323	$	51.53	2,137	$	48.62	3,778	$	43.47

The following weighted-average assumptions were used in determining the fair values of stock options using the Black-Scholes valuation model:

	2011
Expected dividend yield	0	%
Expected stock price volatility	20	%
Risk-free interest rate	2.13	%
Expected life of options (years)	4.75

During the years ended December 28, 2013 and December 29, 2012, we did not grant any stock options.

We have not declared cash or stock dividends on our stock in the past and we do not anticipate declaring cash or stock dividends in the foreseeable future. The expected stock price volatility was based on the evaluation of implied volatilities from traded call options on our stock and from call options embedded in our convertible debt, historical volatility of our stock and other factors. The risk-free interest rate was based on the U.S. Treasury yield curve in effect on the date of grant in conjunction with considering the expected life of options. The expected life of options represented the approximate period of time that granted options were expected to be outstanding and was based on historical data, including, among other things, option exercises, forfeitures and cancellations. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by recipients of stock options, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by us.

The following table represents the intrinsic values of:

	As of
	December 28,		December 29,		December 31,
	2013		2012		2011
Stock options outstanding	$	83,252	$	67,044	$	80,821
Stock options exercisable		83,252		66,964		79,202

The total cash received as a result of stock option exercises for the years ended December 28, 2013, December 29, 2012 and December 31, 2011 was approximately $35.6 million, $72.5 million and $34.5 million. In connection with these exercises, the tax benefits that we realized for the years ended December 28, 2013, December 29, 2012 and December 31, 2011 were $18.4 million, $31.6 million and $7.2 million. We settle employee stock option exercises with newly issued common shares.

The total intrinsic value per share of restricted stock (including restricted stock units) that vested was $98.99, $75.98 and $66.78 during the years ended December 28, 2013, December 29, 2012 and December 31, 2011. The following table summarizes the status of our non-vested restricted shares/units for the year ended December 28, 2013:


	Time-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,018	$	56.87
Granted	217		90.23
Vested	(280)		35.59
Forfeited	(29)		70.06
Outstanding at end of period	926	$	70.70	$	114.43

	Performance-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,315	$	53.27
Granted	149		83.34
Vested	(363)		56.55
Forfeited	(23)		74.78
Outstanding at end of period	1,078	$	59.85	$	114.43

401(k) Plans

We offer qualified 401(k) plans to substantially all our domestic full-time employees. As determined by our Board of Directors, matching contributions to these plans generally do not exceed 100% of the participants' contributions up to 7% of their base compensation, subject to applicable legal limits. Matching contributions consist of cash and were allocated entirely to the participants' investment elections on file, subject to a 20% allocation limit to the Henry Schein Stock Fund. Forfeitures attributable to participants whose employment terminates prior to becoming fully vested are used to reduce our matching contributions and offset administrative expenses of the 401(k) plans.

Assets of the 401(k) and other defined contribution plans are held in self-directed accounts enabling participants to choose from various investment fund options. Matching contributions and administrative expenses related to these plans charged to operations during the years ended December 28, 2013, December 29, 2012 and December 31, 2011 amounted to $25.3 million, $23.8 million and $23.0 million.

Supplemental Executive Retirement Plan

We offer an unfunded, non-qualified supplemental executive retirement plan to eligible employees. This plan generally covers officers and certain highly-compensated employees after they have reached the maximum IRS allowed pre-tax 401(k) contribution limit. Our contributions to this plan are equal to the 401(k) employee-elected contribution percentage applied to base compensation for the portion of the year in which such employees are not eligible to make pre-tax contributions to the 401(k) plan. The amounts charged to operations during the years ended December 28, 2013, December 29, 2012 and December 31, 2011 amounted to $4.1 million, $2.1 million and $0.7 million.

Deferred Compensation Plan

During 2011, we began to offer a deferred compensation plan to a select group of management or highly compensated employees of the Company and certain associated companies. This plan allows for the elective deferral of base salary, bonus and/or commission compensation by eligible employees. The amounts charged to operations during the years ended December 28, 2013, December 29, 2012 and December 31, 2011 were approximately $1.1 million, $0.3 million and $0, respectively.

Commitments and Contingencies

12 Months Ended

Dec. 28, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 17 – Commitments and Contingencies

Operating Leases

We lease facilities and equipment under non-cancelable operating leases expiring through 2033. We expect that in the normal course of business, leases will be renewed or replaced by other leases.

Future minimum annual rental payments under our non-cancelable operating leases as of December 28, 2013 were:

2014		$	75,394
2015			61,238
2016			45,154
2017			32,369
2018			26,497
Thereafter			61,680
	Total minimum operating lease payments	$	302,332

Total rental expense for the years ended December 28, 2013, December 29, 2012 and December 31, 2011 was $70.8 million, $68.2 million and $65.5 million.

Capital Leases

We lease certain equipment under capital leases. Future minimum annual lease payments under our capital leases together with the present value of the minimum capital lease payments as of December 28, 2013 were:

2014		$	847
2015			487
2016			269
2017			35
2018			-
Thereafter			-
Total minimum capital lease payments			1,638
	Less: Amount representing interest at 2.00% to 16.44%		(128)
	Total present value of minimum capital lease payments	$	1,510

Capital Expenditures

We sometimes enter into certain commitments regarding capital expenditures. As of December 28, 2013, we have capital expenditure commitments of $1.6 million due within one year.

Purchase Commitments

In our health care distribution business, we sometimes enter into long-term purchase commitments to ensure the availability of products for distribution. Future minimum annual payments for inventory purchase commitments as of December 28, 2013 were:

2014		$	41,920
2015			22,076
2016			22,457
2017			23,580
2018			24,759
Thereafter			53,294
	Total minimum inventory purchase commitment payments	$	188,086

Litigation

From time to time, we may become a party to legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations, and other matters arising out of the ordinary course of our business. In our opinion, pending matters will not have a material adverse effect on our financial condition or results of operations.

As of December 28, 2013, we had accrued our best estimate of potential losses relating to claims that were probable to result in a liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other external factors, including probable recoveries from third parties.

Employment, Consulting and Non-Compete Agreements

We have definite-lived employment, consulting and non-compete agreements that have varying base aggregate annual payments for the years 2014 through 2018 and thereafter of approximately $13.0 million, $2.7 million, $2.1 million, $2.5 million, $0.2 million and $2.2 million. We also have lifetime consulting agreements that provide for current compensation of $0.5 million per year, increasing $25 every fifth year with the next increase in 2017. In addition, some agreements have provisions for additional incentives and compensation.

Quarterly Information (Unaudited)

12 Months Ended

Dec. 28, 2013

Quarterly Financial Data [Abstract]

Quarterly Information (Unaudited)

Note 18 – Quarterly Information (Unaudited)

The following tables present certain quarterly financial data:

		Quarters ended
		March 30,		June 29,		September 28,		December 28,
		2013 (1)		2013		2013 (2) (3)		2013
Net sales		$	2,293,511	$	2,391,810	$	2,348,956	$	2,526,370
Gross profit			646,991		669,856		639,647		699,520
Operating income			153,629		176,065		160,477		186,883
Net income			98,686		121,435		116,372		134,969

Amounts attributable to
	Henry Schein, Inc.:
Net income			91,478		108,430		107,378		124,268

Earnings per share attributable to
	Henry Schein, Inc.:

	Basic	$	1.06	$	1.26	$	1.25	$	1.46
	Diluted		1.03		1.23		1.23		1.43

		Quarters ended
		March 31,		June 30,		September 29,		December 29,
		2012 (4)		2012		2012		2012
Net sales		$	2,099,019	$	2,201,452	$	2,231,058	$	2,408,438
Gross profit			610,579		624,395		609,044		663,495
Operating income			133,295		154,702		149,622		181,342
Net income			89,061		107,302		105,310		121,715

Amounts attributable to
	Henry Schein, Inc.:
Net income			80,752		98,086		96,771		112,467

Earnings per share attributable to
	Henry Schein, Inc.:

	Basic	$	0.92	$	1.11	$	1.11	$	1.29
	Diluted		0.89		1.08		1.08		1.26


(1)	See Note 5 - "Debt" for details of expenses related to the refinancing of HSAH debt incurred during the first quarter
	of 2013.
(2)	See Note 9 - "Business Acquisitions, Divestiture and Other Transaction" for details of the loss on sale of equity
	investment incurred during the third quarter of 2013.
(3)	See Note 12 - "Incomes Taxes" for details of the reduction of our valuation allowance related to certain deferred tax
	assets incurred during the third quarter of 2013.
(4)	See Note 10 - "Plans of Restructuring" for details of the restructuring costs incurred during the first quarter of 2012.

We experience fluctuations in quarterly earnings. As a result, we may fail to meet or exceed the expectations of securities analysts and investors, which could cause our stock price to decline.

Our business is subject to seasonal and other quarterly fluctuations. Net sales and operating profits generally have been higher in the third and fourth quarters due to the timing of sales of seasonal products (including influenza vaccine, equipment and software products), purchasing patterns of office-based health care practitioners and year-end promotions. Net sales and operating profits generally have been lower in the first quarter, primarily due to increased sales in the prior two quarters. We expect our historical seasonality of sales to continue in the foreseeable future. Quarterly results also may be adversely affected by a variety of other factors, including:

• timing and amount of sales and marketing expenditures;

• timing of pricing changes offered by our vendors;

• timing of the introduction of new products and services by our vendors;

• timing of the release of upgrades and enhancements to our technology-related products and services;

• changes in or availability of vendor contracts or rebate programs;

• vendor rebates based upon attaining certain growth goals;

• changes in the way vendors introduce or deliver products to market;

• costs of developing new applications and services;

• our ability to correctly identify customer needs and preferences and predict future needs and preferences;

• exclusivity requirements with certain vendors may prohibit us from distributing competitive products manufactured by other vendors;

• loss of sales representatives;

• costs related to acquisitions and/or integrations of technologies or businesses;

• costs associated with our self-insured medical and dental insurance programs;

• general market and economic conditions, as well as those specific to the health care industry and related industries;

• our success in establishing or maintaining business relationships;

• unexpected difficulties in developing and manufacturing products;

• product demand and availability or recalls by manufacturers;

• exposure to product liability and other claims in the event that the use of the products we sell results in injury;

• increases in the cost of shipping or service issues with our third-party shippers;

• restructuring costs; and

• changes in accounting principles.

Any change in one or more of these or other factors could cause our annual or quarterly operating results to fluctuate. If our operating results do not meet market expectations, our stock price may decline.

Supplemental Cash Flow Information

12 Months Ended

Dec. 28, 2013

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information

Note 19 – Supplemental Cash Flow Information

Cash paid for interest and income taxes was:

	Years ended
	December 28,		December 29,		December 31,
	2013		2012		2011
Interest	$	19,893	$	23,358	$	30,847
Income taxes		146,593		196,765		173,318

There was approximately $0.1 million, $8.3 million and $16.7 million of debt assumed as a part of the acquisitions for the years ended December 28, 2013, December 29, 2012 and December 31, 2011, respectively. Debt assumed during the years ended December 29, 2012 and December 31, 2011 primarily relates to the acquisitions of C&M Vetlink and Provet Holdings Limited, respectively.

For the years ended December 28, 2013, December 29, 2012 and December 31, 2011, we had $0.1 million, $3.5 million and $(0.7) million of non-cash net unrealized gains (losses) related to foreign currency hedging activities, respectively.

Schedule II - Valuation and Qualifying Accounts

12 Months Ended

Dec. 28, 2013

Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts

Schedule II
Valuation and Qualifying Accounts

					Additions
			Balance at		Charged to		Charged to				Balance at
			beginning of		statement of		other				end of
Description			period		income (1)		accounts (2)		Deductions (3)		period

Year ended December 28, 2013:
	Allowance for doubtful accounts,
		sales returns and other	$	75,240	$	5,189	$	6,195	$	(8,326)	$	78,298

Year ended December 29, 2012:
	Allowance for doubtful accounts,
		sales returns and other	$	65,853	$	4,407	$	13,305	$	(8,325)	$	75,240

Year ended December 31, 2011:
	Allowance for doubtful accounts,
		sales returns and other	$	56,267	$	6,156	$	9,665	$	(6,235)	$	65,853

(1)	Represents amounts charged to bad debt expense.

(2)	Amounts charged to net sales primarily relate to increases in allowances for sales returns.

(3)	Deductions primarily consist of fully reserved accounts receivable that have been written off.

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 28, 2013
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation Our consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates, which are greater than or equal to 20% and less than or equal to 50% owned or investments in unconsolidated affiliates of less than 20% in which we have the ability to influence the operating or financial decisions, are accounted for under the equity method. See Note 6 for accounting treatment of Redeemable noncontrolling interests. Certain prior period amounts have been reclassified to conform to the current period presentation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Fiscal Year	Fiscal Year We report our results of operations and cash flows on a 52-53 week basis ending on the last Saturday of December. The years ended December 28, 2013 and December 29, 2012 consisted of 52 weeks and the year ended December 31, 2011 consisted of 53 weeks.
Revenue Recognition	Revenue Recognition We generate revenue from the sale of dental, animal health and medical consumable products, as well as equipment, software products and services and other sources. Provisions for discounts, rebates to customers, customer returns and other contra-revenue adjustments are recorded based upon historical data and estimates and are provided for in the period in which the related sales are recognized. Revenue derived from the sale of consumable products is recognized when products are shipped to customers. Such sales typically entail high-volume, low-dollar orders shipped using third-party common carriers. We believe that the shipment date is the most appropriate point in time indicating the completion of the earnings process because we have no post-shipment obligations, the product price is fixed and determinable, collection of the resulting receivable is reasonably assured and product returns are reasonably estimable. Revenue derived from the sale of equipment is recognized when products are delivered to customers. Such sales typically entail scheduled deliveries of large equipment primarily by equipment service technicians. Some equipment sales require minimal installation, which is typically completed at the time of delivery. Revenue derived from the sale of software products is recognized when products are shipped to customers. Such software is generally installed by customers and does not require extensive training due to the nature of its design. Revenue derived from post-contract customer support for software, including annual support and/or training, is recognized over the period in which the services are provided. Revenue derived from multiple element arrangements, and the related deferral of such revenue (which is insignificant to our financial statements), is recognized as follows. When we sell software products together with related services (i.e., training and technical support) we allocate revenue to the delivered elements using the residual method, based upon vendor-specific objective evidence (“VSOE”) of the fair value of the undelivered elements, or defer it until such time as vendor-specific evidence of fair value is obtained. Multiple element arrangements that include elements that are not considered software consist primarily of equipment and the related installation service. Effective December 26, 2010 we allocate revenue for such arrangements based on the relative selling prices of the elements applying the following hierarchy: first VSOE, then third-party evidence (“TPE”) of selling price if VSOE is not available, and finally our estimate of the selling price if neither VSOE nor TPE is available. VSOE exists when we sell the deliverables separately and represents the actual price charged by us for each deliverable. Estimated selling price reflects our best estimate of what the selling prices of each deliverable would be if it were sold regularly on a standalone basis taking into consideration the cost structure of our business, technical skill required, customer location and other market conditions. Each element that has standalone value is accounted for as a separate unit of accounting. Revenue allocated to each unit of accounting is recognized when the service is provided or the product is delivered. Revenue derived from other sources including freight charges, equipment repairs and financial services, is recognized when the related product revenue is recognized or when the services are provided.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid short-term investments with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Outstanding checks in excess of funds on deposit of $39.6 million and $59.4 million, primarily related to payments for inventory, were classified as accounts payable as of December 28, 2013 and December 29, 2012.
Accounts Receivable and Reserves	Accounts Receivable and Reserves The carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate of the amounts that will not be collected. The reserve for accounts receivable is comprised of allowance for doubtful accounts and sales returns. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserve, including historical data, experience, customer types, credit worthiness and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect collectability.
Inventories and Reserves	Inventories and Reserves Inventories consist primarily of finished goods and are valued at the lower of cost or market. Cost is determined by the first-in, first-out method for merchandise or actual cost for large equipment and high tech equipment. In accordance with our policy for inventory valuation, we consider many factors including the condition and salability of the inventory, historical sales, forecasted sales and market and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect the value of inventory.
Direct Shipping and Handling Costs	Direct Shipping and Handling Costs Freight and other direct shipping costs are included in cost of sales. Direct handling costs, which represent primarily direct compensation costs of employees who pick, pack and otherwise prepare, if necessary, merchandise for shipment to our customers are reflected in selling, general and administrative expenses. Direct shipping and handling costs were $69.1 million, $64.5 million and $62.5 million for the years ended December 28, 2013, December 29, 2012 and December 31, 2011.
Advertising and Promotional Costs	Advertising and Promotional Costs We generally expense advertising and promotional costs as incurred. Total advertising and promotional expenses were $12.2 million, $10.4 million and $13.1 million for the years ended December 28, 2013, December 29, 2012 and December 31, 2011. Additionally, advertising and promotional costs incurred in connection with direct marketing, including product catalogs and printed material, are deferred and amortized on a straight-line basis over the period which is benefited, generally not exceeding one year. As of December 28, 2013 and December 29, 2012, we had $3.9 million and $3.9 million of deferred direct marketing expenses included in other current assets.
Supplier Rebates	Supplier Rebates Supplier rebates are included as a reduction of cost of sales and are recognized over the period they are earned. The factors we consider in estimating supplier rebate accruals include forecasted inventory purchases and sales, in conjunction with supplier rebate contract terms, which generally provide for increasing rebates based on either increased purchase or sales volume.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is computed primarily under the straight-line method (see Note 2 - Property and Equipment, Net for estimated useful lives). Amortization of leasehold improvements is computed using the straight-line method over the lesser of the useful life of the assets or the lease term. Capitalized software costs consist of costs to purchase and develop software. Costs incurred during the application development stage for software bought and further customized by outside suppliers for our use and software developed by a supplier for our proprietary use are capitalized. Costs incurred for our own personnel who are directly associated with software development are capitalized.
Income Taxes	Income Taxes We account for income taxes under an asset and liability approach that requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in tax laws or rates. The effect on deferred income tax assets and liabilities of a change in tax rates will be recognized as income or expense in the period that includes the enactment date. We file a consolidated U.S. federal income tax return with our 80% or greater owned U.S. subsidiaries.
Foreign Currency Translation and Transactions	Foreign Currency Translation and Transactions The financial position and results of operations of our foreign subsidiaries are determined using local currency as the functional currency. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each year-end. Income statement accounts are translated at the average rate of exchange prevailing during the year. Translation adjustments arising from the use of differing exchange rates from period to period are included in Accumulated other comprehensive income in stockholders' equity. Gains and losses resulting from foreign currency transactions are included in earnings.
Risk Management and Derivative Financial Instruments	Risk Management and Derivative Financial Instruments We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our objective is to manage the impact that foreign currency exchange rate fluctuations could have on recognized asset and liability fair values, earnings and cash flows. Our risk management policy requires that derivative contracts used as hedges be effective at reducing the risks associated with the exposure being hedged and be designated as a hedge at the inception of the contract. We do not enter into derivative instruments for speculative purposes. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans and certain forecasted inventory purchase commitments with foreign suppliers. Our foreign currency forward agreements related to forecasted inventory purchase commitments are designated as cash flow hedges. Our foreign currency forward agreements related to foreign currency balance sheet exposure provide economic hedges but are not designated as hedges for accounting purposes. For agreements not designated as hedges, changes in the value of the derivative, along with the transaction gain or loss on the hedged item, are recorded in earnings. For cash flow hedges, the effective portion of the changes in the fair value of the derivative, along with any gain or loss on the hedged item, is recorded as a component of Accumulated other comprehensive income in stockholders' equity and subsequently reclassified into earnings in the period(s) during which the hedged transaction affects earnings. We classify the cash flows related to our hedging activities in the same category on our consolidated statements of cash flows as the cash flows related to the hedged item.
Acquisitions	Acquisitions The net assets of businesses purchased are recorded at their fair value at the acquisition date and our consolidated financial statements include their results of operations from that date. Any excess of acquisition consideration over the fair value of identifiable net assets acquired is recorded as goodwill. The major classes of assets and liabilities that we generally allocate purchase price to, excluding goodwill, include identifiable intangible assets (i.e., trademarks and trade names, customer relationships and lists and non-compete agreements), property, plant and equipment, deferred taxes and other current and long-term assets and liabilities. The estimated fair value of identifiable intangible assets is based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; customer retention rates; and estimated useful lives. Some prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. For the years ended December 28, 2013, December 29, 2012 and December 31, 2011, there were no material adjustments recorded in our consolidated statement of income relating to changes in estimated contingent purchase price liabilities.
Redeemable Noncontrolling Interests	Redeemable Noncontrolling Interests Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Their interests in these subsidiaries are classified outside permanent equity on our consolidated balance sheets and are carried at the estimated redemption amounts. The redemption amounts have been estimated based on expected future earnings and cash flow and, if such earnings and cash flow are not achieved, the value of the redeemable noncontrolling interests might be impacted. Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are reflected at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.
Goodwill and Other Indefinite-Lived Intangibles Assets	Goodwill and Other Indefinite-Lived Intangible Assets Goodwill and other indefinite-lived intangible assets (primarily trademarks) are not amortized, but are subject to impairment analysis at least once annually. Such impairment analyses for goodwill require a comparison of the fair value to the carrying value of reporting units. We regard our reporting units to be our operating segments: health care distribution (global dental, animal health and medical) and technology and value-added services. We test goodwill for impairment under the provisions of Accounting Standards Update 2011-08, “Intangibles-Goodwill and Other (Topic 350): Testing Goodwill for Impairment” (“ASU 2011-08”), which allows us to use qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than their carrying values. The factors that we consider in developing our qualitative assessment included: Macroeconomic conditions consisting of the overall sales growth of our business and the overall sales growth of each of our operating segments. We also consider our growth in market share in the markets in which we compete; Credit markets and our ability to access debt facilities at favorable terms; Key personnel and management expertise, as well as our growth strategies for the next several years; and Our expectations of selling or disposing all, or a portion, of a reporting unit. Goodwill was allocated to such reporting units, for the purposes of preparing our impairment analyses, based on a specific identification basis. Our impairment analysis for indefinite-lived intangibles consists of a comparison of the fair value to the carrying value of the assets. This comparison is made based on a review of historical, current and forecasted sales and gross profit levels, as well as a review of any factors that may indicate potential impairment. For certain indefinite-lived intangible assets, a present value technique, such as estimates of future cash flows, is utilized. We assessed the potential impairment of goodwill and other indefinite-lived intangible assets annually (at the beginning of our fourth quarter) and on an interim basis whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Some factors we consider important that could trigger an interim impairment review include: significant underperformance relative to expected historical or projected future operating results; significant changes in the manner of our use of acquired assets or the strategy for our overall business (e.g., decision to divest a business); or significant negative industry or economic trends. If we determine through the impairment review process that goodwill or other indefinite-lived intangible assets are impaired, we record an impairment charge in our consolidated statements of income. Beginning with the first quarter of 2012, we changed our reporting units from dental, medical, animal health, international and technology to global dental, global animal health, global medical and global technology and value-added services. These groups have been formed to provide distinct organizational focus for reaching and serving each practitioner segment with the benefits of a global perspective, as well as global product and service offerings and best practices. In connection with this change in business groups, goodwill was reallocated to the new reporting units. Based upon this change, we felt it was necessary to perform a quantitative assessment, in addition to a qualitative assessment, of goodwill impairment as of the first day of the fourth quarter for the year ended December 29, 2012 in order to establish a new baseline calculation. Based on a qualitative analysis, there were no events or circumstances from the date of that assessment through December 28, 2013 that impacted our analysis. For the years ended December 28, 2013, December 29, 2012 and December 31, 2011, the results of our goodwill impairment analysis did not result in any impairments.
Long-Lived Assets	Long-Lived Assets Long-lived assets, other than goodwill and other indefinite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows derived from such assets. Definite-lived intangible assets primarily consist of non-compete agreements, trademarks, trade names, customer lists, customer relationships and intellectual property. For long-lived assets used in operations, impairment losses are only recorded if the asset's carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. We measure the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.
Cost of Sales	Cost of Sales The primary components of cost of sales include the cost of the product (net of purchase discounts, supplier chargebacks and rebates) and inbound and outbound freight charges. Costs related to purchasing, receiving, inspections, warehousing, internal inventory transfers and other costs of our distribution network are included in selling, general and administrative expenses along with other operating costs. As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Total distribution network costs were $62.2 million, $59.5 million and $59.1 million for the years ended December 28, 2013, December 29, 2012 and December 31, 2011.
Comprehensive Income	Comprehensive Income Comprehensive income includes certain gains and losses that, under accounting principles generally accepted in the United States, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders' equity. Our comprehensive income is primarily comprised of net income, foreign currency translation adjustments, unrealized gains (losses) on hedging and investment activity and pension adjustments.

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 28, 2013

Property, Plant and Equipment [Abstract]

Property and equipment, including related estimated useful lives

			December 28,		December 29,
			2013		2012
Land			$	19,981	$	13,531
Buildings and permanent improvements				112,514		112,979
Leasehold improvements				73,974		70,725
Machinery and warehouse equipment				71,129		68,432
Furniture, fixtures and other				118,806		102,569
Computer equipment and software				279,831		258,962
				676,235		627,198
Less accumulated depreciation				(400,347)		(353,740)
	Property and equipment, net		$	275,888	$	273,458



			Estimated Useful
			Lives (in years)
		Buildings and permanent improvements	40
		Machinery and warehouse equipment	5-10
		Furniture, fixtures and other	3-10
		Computer equipment and software	3-10

Goodwill and Other Intangibles, Net (Tables)

12 Months Ended

Dec. 28, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in the Carrying Amount of Goodwill

			Health Care Distribution		Technology and Value-Added Services		Total
Balance as of December 31, 2011			$	1,398,248	$	98,860	$	1,497,108
	Adjustments to goodwill:
		Acquisitions		30,765		61,788		92,553
		Foreign currency translation		9,909		1,476		11,385
Balance as of December 29, 2012				1,438,922		162,124		1,601,046
	Adjustments to goodwill:
		Acquisitions		22,055		6,369		28,424
		Foreign currency translation		4,361		1,174		5,535
Balance as of December 28, 2013			$	1,465,338	$	169,667	$	1,635,005

Other Intangible Assets - Finite-lived


	December 28, 2013						December 29, 2012
			Accumulated						Accumulated
	Cost		Amortization		Net		Cost		Amortization		Net
Non-compete agreements	$	44,162	$	(9,666)	$	34,496	$	47,351	$	(7,949)	$	39,402
Trademarks / trade names - definite lived		77,134		(27,794)		49,340		72,948		(18,474)		54,474
Trademarks / trade names - indefinite lived		3,717		-		3,717		3,681		-		3,681
Customer relationships and lists		478,852		(193,263)		285,589		504,387		(179,566)		324,821
Other		68,844		(24,853)		43,991		57,397		(17,593)		39,804
Total	$	672,709	$	(255,576)	$	417,133	$	685,764	$	(223,582)	$	462,182

Other Intangible Assets - Indefinite-lived


	December 28, 2013						December 29, 2012
			Accumulated						Accumulated
	Cost		Amortization		Net		Cost		Amortization		Net
Non-compete agreements	$	44,162	$	(9,666)	$	34,496	$	47,351	$	(7,949)	$	39,402
Trademarks / trade names - definite lived		77,134		(27,794)		49,340		72,948		(18,474)		54,474
Trademarks / trade names - indefinite lived		3,717		-		3,717		3,681		-		3,681
Customer relationships and lists		478,852		(193,263)		285,589		504,387		(179,566)		324,821
Other		68,844		(24,853)		43,991		57,397		(17,593)		39,804
Total	$	672,709	$	(255,576)	$	417,133	$	685,764	$	(223,582)	$	462,182

Investments and Other (Tables)

12 Months Ended

Dec. 28, 2013

Investments And Other [Abstract]

Investments and Other

		December 28,		December 29,
		2013		2012
Investment in unconsolidated affiliates		$	205,556	$	191,075
Non-current deferred foreign, state and local income taxes			48,470		37,737
Notes receivable (1)			10,836		9,851
Auction rate securities, net of temporary impairment			2,654		2,816
Distribution rights and exclusivity agreements, net of amortization			3,321		4,030
Security deposits			3,341		3,291
Debt issuance costs, net of amortization			2,011		7,207
Acquisition related indemnification			13,880		14,168
Acquisition related loan receivable (2)			145,000		-
Other long-term assets			26,876		22,759
	Total	$	461,945	$	292,934


(1)	Long-term notes receivable carry interest rates ranging from 2.17% to 12.0% and are due in varying installments through
	December 31, 2020.

(2)	See Note 9 - Business Acquisitions, Divestiture and Other Transaction for additional details of the loan receivable from
	BioHorizons, Inc.

Debt (Tables)

12 Months Ended

Dec. 28, 2013

Debt Disclosure [Abstract]

Private Placement Facilities


	Amount of
	Borrowing		Borrowing
Date of Borrowing	Outstanding		Rate		Due Date
September 2, 2010	$	100,000	3.79	%	September 2, 2020
January 20, 2012		50,000	3.45		January 20, 2024
January 20, 2012 (1)		50,000	3.09		January 20, 2022
December 24, 2012		50,000	3.00		December 24, 2024
	$	250,000


(1) Annual repayments of approximately $7.1 million for this borrowing will commence on January 20, 2016.

Schedule of long-term debt

		December 28,		December 29,
		2013		2012
Private placement facilities		$	250,000	$	250,000
U.S. trade accounts receivable securitization			160,000		-
Notes payable to banks at a weighted-average interest rate of 8.23%			73		11,352
Butler Schein Animal Health Supply notes payable to banks (net of discount of
	$0 million and $0.7 million)		-		220,439
Various collateralized and uncollateralized loans payable with interest,
	in varying installments through 2018 at interest rates ranging
	from 2.4% to 5.41%		44,091		21,178
Capital lease obligations (see Note 17)			1,510		3,144
Total			455,674		506,113
Less current maturities			(5,441)		(17,992)
	Total long-term debt	$	450,233	$	488,121

Schedule of long-term debt maturities

2014		$	5,441
2015			3,223
2016			170,336
2017			17,801
2018			30,302
Thereafter			228,571
	Total	$	455,674

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

+ Details

Redeemable Noncontrolling Interests (Tables)

12 Months Ended

Dec. 28, 2013

Temporary Equity Disclosure [Abstract]

Change in fair value of redeemable noncontrolling interests

		December 28,		December 29,		December 31,
		2013		2012		2011
Balance, beginning of period		$	435,175	$	402,050	$	304,140
Decrease in redeemable noncontrolling interests due to
	redemptions		(9,028)		(23,637)		(160,254)
Increase in redeemable noncontrolling interests due to
	business acquisitions		11,542		30,935		13,618
Net income attributable to redeemable noncontrolling interests			39,430		34,803		36,514
Dividends declared			(19,965)		(21,013)		(15,212)
Effect of foreign currency translation gain (loss) attributable to
	redeemable noncontrolling interests		(654)		904		(889)
Change in fair value of redeemable securities			41,039		53,769		224,133
Other adjustment to redeemable noncontrolling interests			-		(42,636)		-
Balance, end of period		$	497,539	$	435,175	$	402,050

Comprehensive Income (Tables)

12 Months Ended

Dec. 28, 2013

Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]

Accumulated other comprehensive income, net of applicable taxes

		December 28,		December 29,		December 31,
		2013		2012		2011
Attributable to Redeemable noncontrolling interests:
	Foreign currency translation adjustment	$	(1,503)	$	(849)	$	(1,753)

Attributable to Henry Schein, Inc.:
Foreign currency translation gain		$	82,288	$	72,160	$	39,717
Unrealized gain (loss) from foreign currency hedging activities			1,282		1,187		(1,678)
Unrealized investment loss			(515)		(415)		(829)
Pension adjustment loss			(15,206)		(20,077)		(14,626)
	Accumulated other comprehensive income	$	67,849	$	52,855	$	22,584

Total Accumulated other comprehensive income		$	66,346	$	52,006	$	20,831

Components of comprehensive income, net of applicable taxes

	December 28,		December 29,		December 31,
	2013		2012		2011
Net income	$	471,462	$	423,388	$	404,656

Foreign currency translation gain (loss)		9,474		33,347		(2,310)
Tax effect		-		-		-
Foreign currency translation gain (loss)		9,474		33,347		(2,310)

Unrealized gain (loss) from foreign currency hedging activities		69		3,519		(712)
Tax effect		26		(654)		94
Unrealized gain (loss) from foreign currency hedging activities		95		2,865		(618)

Unrealized investment gain (loss)		(166)		724		562
Tax effect		66		(310)		(215)
Unrealized investment gain (loss)		(100)		414		347

Pension adjustment gain (loss)		6,207		(7,638)		(7,772)
Tax effect		(1,336)		2,187		1,534
Pension adjustment gain (loss)		4,871		(5,451)		(6,238)

Comprehensive income	$	485,802	$	454,563	$	395,837

Total comprehensive income, net of applicable taxes

		December 28,		December 29,		December 31,
		2013		2012		2011
Comprehensive income attributable to
	Henry Schein, Inc.	$	446,548	$	418,347	$	359,731
Comprehensive income attributable to
	noncontrolling interests		478		509		481
Comprehensive income attributable to
	Redeemable noncontrolling interests		38,776		35,707		35,625
Comprehensive income		$	485,802	$	454,563	$	395,837

Fair Value Measurements (Tables)

12 Months Ended

Dec. 28, 2013

Fair Value Disclosures [Abstract]

Fair value - assets and liabilities measured and recognized on a recurring basis

			December 28, 2013
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts			-		1,235		-		1,235
		Total assets	$	-	$	1,235	$	-	$	1,235

Liabilities:
	Derivative contracts		$	-	$	1,142	$	-	$	1,142
		Total liabilities	$	-	$	1,142	$	-	$	1,142

Redeemable noncontrolling interests			$	-	$	-	$	497,539	$	497,539


			December 29, 2012
				Level 1		Level 2		Level 3		Total

Assets:
	Available-for-sale securities		$	-	$	-	$	2,816	$	2,816
	Derivative contracts			-		710		-		710
		Total assets	$	-	$	710	$	2,816	$	3,526

Liabilities:
	Derivative contracts		$	-	$	1,159	$	-	$	1,159
		Total liabilities	$	-	$	1,159	$	-	$	1,159

Redeemable noncontrolling interests			$	-	$	-	$	435,175	$	435,175

Plans of Restructuring (Tables)

12 Months Ended

Dec. 28, 2013

Restructuring and Related Activities [Abstract]

Schedule of restructuring reserve by type of cost


			Facility
	Severance		Closing
	Costs		Costs		Total
Balance, December 25, 2010		1,992		2,351		4,343
Provision		-		-		-
Payments and other adjustments		(1,423)		(1,800)		(3,223)
Balance, December 31, 2011		569		551		1,120
Provision		12,841		2,351		15,192
Payments and other adjustments		(11,584)		(1,671)		(13,255)
Balance, December 29, 2012		1,826		1,231		3,057
Provision		-		-		-
Payments and other adjustments		(1,599)		(747)		(2,346)
Balance, December 28, 2013	$	227	$	484	$	711

Schedule of restructuring reserve by segment

			Technology and
	Health Care		Value-Added
	Distribution		Services		Total
Balance, December 25, 2010		4,343		-		4,343
Provision		-		-		-
Payments and other adjustments		(3,223)		-		(3,223)
Balance, December 31, 2011		1,120		-		1,120
Provision		14,981		211		15,192
Payments and other adjustments		(13,058)		(197)		(13,255)
Balance, December 29, 2012		3,043		14		3,057
Provision		-		-		-
Payments and other adjustments		(2,332)		(14)		(2,346)
Balance, December 28, 2013	$	711	$	-	$	711

Earnings Per Share (Tables)

12 Months Ended

Dec. 28, 2013

Earnings Per Share [Abstract]

Reconciliation of basic and diluted shares used to calculate earnings per share

		Years Ended
		December 28,	December 29,	December 31,
		2013	2012	2011
Basic		85,926	87,499	90,120
Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	1,696	2,324	2,500
	Diluted	87,622	89,823	92,620

Income Taxes (Tables)

12 Months Ended

Dec. 28, 2013

Income Tax Disclosure [Abstract]

Income before taxes, equity in earnings of affiliates and loss on sale of equity investment

		Years ended
		December 28,		December 29,		December 31,
		2013		2012		2011
Domestic		$	517,950	$	466,457	$	403,171
Foreign			146,744		137,731		166,136
	Total	$	664,694	$	604,188	$	569,307

Provision for income taxes

				Years ended
				December 28,		December 29,		December 31,
				2013		2012		2011
Current income tax expense:
	U.S. Federal			$	139,253	$	121,591	$	125,148
	State and local				27,272		23,279		30,423
	Foreign				35,880		32,916		43,960
		Total current			202,405		177,786		199,531

Deferred income tax expense (benefit):
	U.S. Federal				10,325		9,242		(12,466)
	State and local				(4,531)		946		(1,782)
	Foreign				(17,308)		(116)		(5,071)
		Total deferred			(11,514)		10,072		(19,319)
			Total provision	$	190,891	$	187,858	$	180,212

Tax effects of temporary differences to deferred income tax asset (liability)

			Years Ended
			December 28,		December 29,
			2013		2012
Current deferred income tax assets:
	Inventory, premium coupon redemptions and accounts receivable
		valuation allowances	$	31,016	$	27,820
	Uniform capitalization adjustments to inventories			7,318		9,944
	Other current assets			21,351		21,035
	Current deferred income tax asset (1)			59,685		58,799

Non-current deferred income tax asset (liability):
	Property and equipment			(5,571)		(5,661)
	Stock-based compensation			35,995		42,875
	Other non-current liabilities			(211,180)		(215,562)
	Net operating losses of domestic subsidiaries			693		2,768
	Net operating losses of foreign subsidiaries			45,254		47,101
		Total non-current deferred tax liability		(134,809)		(128,479)
		Valuation allowance for non-current deferred tax assets (2)		(16,285)		(30,598)
	Net non-current deferred tax liability (1)			(151,094)		(159,077)
Net deferred income tax liability			$	(91,409)	$	(100,278)


(1)	Certain deferred tax amounts do not have a right of offset and are therefore reflected on a gross basis in current assets
	and non-current liabilities in our consolidated balance sheets.

(2)	Primarily relates to operating losses of acquired foreign subsidiaries, the benefits of which are uncertain. Any future reductions
	of such valuation allowances will be reflected as a reduction of income tax expense in accordance with the provisions of
	ASC Topic 805, “Business Combinations.”

Reconciliation of income tax provision at federal statutory rate to total income tax provision

		Years ended
		December 28,		December 29,		December 31,
		2013		2012		2011
Income tax provision at federal statutory rate		$	232,644	$	211,466	$	199,256
State income tax provision, net of federal income tax effect			20,134		21,665		18,035
Foreign income tax benefit			(19,635)		(17,979)		(20,169)
Valuation allowance			(14,026)		1,502		442
Interest expense related to loans			(23,723)		(21,018)		(14,394)
Other			(4,503)		(7,778)		(2,958)
	Total income tax provision	$	190,891	$	187,858	$	180,212

Reconciliation of unrecognized tax benefits excluding the effect of deferred taxes

	December 28,		December 29,
	2013		2012
Balance, beginning of period	$	32,700	$	19,200
Additions based on current year tax positions		6,000		4,900
Additions based on prior year tax positions		9,600		11,200
Reductions based on prior year tax positions		(1,100)		(600)
Reductions resulting from settlements with taxing authorities		(800)		(1,300)
Reductions resulting from lapse in statutes of limitations		(3,200)		(700)
Balance, end of period	$	43,200	$	32,700

Segment Data (Tables)

12 Months Ended

Dec. 28, 2013

Segment Reporting [Abstract]

Business segment information

				Years Ended
				December 28,		December 29,		December 31,
				2013		2012		2011
Net Sales:
	Health care distribution (1):
		Dental		$	4,997,972	$	4,774,482	$	4,764,898
		Animal health			2,599,461		2,321,151		2,010,270
		Medical			1,643,167		1,560,921		1,504,454
			Total health care distribution		9,240,600		8,656,554		8,279,622
	Technology and value-added services (2)				320,047		283,413		250,620
		Total		$	9,560,647	$	8,939,967	$	8,530,242


(1)	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
	generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(2)	Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
	and financial and other services, including e-services and continuing education services for practitioners.

			Years ended
			December 28,		December 29,		December 31,
			2013		2012		2011
Operating Income:
	Health care distribution		$	590,664	$	541,667	$	512,094
	Technology and value-added services			86,390		77,294		70,055
		Total	$	677,054	$	618,961	$	582,149

Income before taxes and equity in earnings of affiliates
	Health care distribution		$	581,759	$	529,236	$	501,266
	Technology and value-added services			82,935		74,952		68,041
		Total	$	664,694	$	604,188	$	569,307

Depreciation and Amortization:
	Health care distribution		$	113,670	$	113,688	$	106,485
	Technology and value-added services			14,365		11,634		9,411
		Total	$	128,035	$	125,322	$	115,896

Income Tax Expense:
	Health care distribution		$	165,869	$	165,346	$	157,391
	Technology and value-added services			25,022		22,512		22,821
		Total	$	190,891	$	187,858	$	180,212

Interest Income:
	Health care distribution		$	12,816	$	13,293	$	15,531
	Technology and value-added services			37		101		62
		Total	$	12,853	$	13,394	$	15,593

Interest Expense:
	Health care distribution		$	27,375	$	30,790	$	30,350
	Technology and value-added services			163		112		27
		Total	$	27,538	$	30,902	$	30,377

Purchases of Fixed Assets:
	Health care distribution		$	57,364	$	47,057	$	42,751
	Technology and value-added services			2,851		4,180		2,425
		Total	$	60,215	$	51,237	$	45,176

			As of
			December 28,		December 29,		December 31,
			2013		2012		2011
Total Assets:
	Health care distribution		$	5,277,354	$	5,001,188	$	4,542,331
	Technology and value-added services			347,282		332,809		197,813
		Total	$	5,624,636	$	5,333,997	$	4,740,144

Operations by geographic area

		2013				2012				2011
		Net Sales		Long-Lived Assets		Net Sales		Long-Lived Assets		Net Sales		Long-Lived Assets
United States		$	5,813,512	$	1,272,683	$	5,496,969	$	1,313,866	$	5,212,861	$	1,279,913
Other			3,747,135		1,055,343		3,442,998		1,022,820		3,317,381		888,895
	Consolidated total	$	9,560,647	$	2,328,026	$	8,939,967	$	2,336,686	$	8,530,242	$	2,168,808

Employee Benefit Plans (Tables)

12 Months Ended

Dec. 28, 2013

Summary of the stock option activity under the plans

	Years Ended
	December 28,			December 29,			December 31,
	2013			2012			2011

		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at beginning of year	2,138	$	48.61	4,059	$	44.53	5,012	$	43.05
Granted	-		-	-		-	10		69.45
Exercised	(815)		43.86	(1,890)		40.06	(942)		36.84
Forfeited	-		-	(31)		36.02	(21)		48.35
Outstanding at end of year	1,323	$	51.53	2,138	$	48.61	4,059	$	44.53

Options exercisable at end of year	1,323	$	51.53	2,137	$	48.62	3,778	$	43.47

Weighted-average assumptions used in determining the fair values of stock options using the black-scholes valuation model

	2011
Expected dividend yield	0	%
Expected stock price volatility	20	%
Risk-free interest rate	2.13	%
Expected life of options (years)	4.75

Intrinsic values

	As of
	December 28,		December 29,		December 31,
	2013		2012		2011
Stock options outstanding	$	83,252	$	67,044	$	80,821
Stock options exercisable		83,252		66,964		79,202

Status of non-vested restricted shares/units


	Time-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,018	$	56.87
Granted	217		90.23
Vested	(280)		35.59
Forfeited	(29)		70.06
Outstanding at end of period	926	$	70.70	$	114.43

	Performance-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,315	$	53.27
Granted	149		83.34
Vested	(363)		56.55
Forfeited	(23)		74.78
Outstanding at end of period	1,078	$	59.85	$	114.43

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 28, 2013

Commitments and Contingencies Disclosure [Abstract]

Operating leases

2014		$	75,394
2015			61,238
2016			45,154
2017			32,369
2018			26,497
Thereafter			61,680
	Total minimum operating lease payments	$	302,332

Capital leases

2014		$	847
2015			487
2016			269
2017			35
2018			-
Thereafter			-
Total minimum capital lease payments			1,638
	Less: Amount representing interest at 2.00% to 16.44%		(128)
	Total present value of minimum capital lease payments	$	1,510

Purchase commitments

2014		$	41,920
2015			22,076
2016			22,457
2017			23,580
2018			24,759
Thereafter			53,294
	Total minimum inventory purchase commitment payments	$	188,086

Quarterly Information (Unaudited) (Tables)

12 Months Ended

Dec. 28, 2013

Quarterly Financial Data [Abstract]

Quarterly financial information (unaudited)

		Quarters ended
		March 30,		June 29,		September 28,		December 28,
		2013 (1)		2013		2013 (2) (3)		2013
Net sales		$	2,293,511	$	2,391,810	$	2,348,956	$	2,526,370
Gross profit			646,991		669,856		639,647		699,520
Operating income			153,629		176,065		160,477		186,883
Net income			98,686		121,435		116,372		134,969

Amounts attributable to
	Henry Schein, Inc.:
Net income			91,478		108,430		107,378		124,268

Earnings per share attributable to
	Henry Schein, Inc.:

	Basic	$	1.06	$	1.26	$	1.25	$	1.46
	Diluted		1.03		1.23		1.23		1.43

		Quarters ended
		March 31,		June 30,		September 29,		December 29,
		2012 (4)		2012		2012		2012
Net sales		$	2,099,019	$	2,201,452	$	2,231,058	$	2,408,438
Gross profit			610,579		624,395		609,044		663,495
Operating income			133,295		154,702		149,622		181,342
Net income			89,061		107,302		105,310		121,715

Amounts attributable to
	Henry Schein, Inc.:
Net income			80,752		98,086		96,771		112,467

Earnings per share attributable to
	Henry Schein, Inc.:

	Basic	$	0.92	$	1.11	$	1.11	$	1.29
	Diluted		0.89		1.08		1.08		1.26


(1)	See Note 5 - "Debt" for details of expenses related to the refinancing of HSAH debt incurred during the first quarter
	of 2013.
(2)	See Note 9 - "Business Acquisitions, Divestiture and Other Transaction" for details of the loss on sale of equity
	investment incurred during the third quarter of 2013.
(3)	See Note 12 - "Incomes Taxes" for details of the reduction of our valuation allowance related to certain deferred tax
	assets incurred during the third quarter of 2013.
(4)	See Note 10 - "Plans of Restructuring" for details of the restructuring costs incurred during the first quarter of 2012.

Supplemental Cash Flow Information (Tables)

12 Months Ended

Dec. 28, 2013

Supplemental Cash Flow Elements [Abstract]

Cash paid for interest and income taxes

	Years ended
	December 28,		December 29,		December 31,
	2013		2012		2011
Interest	$	19,893	$	23,358	$	30,847
Income taxes		146,593		196,765		173,318

Significant Account Policies (Details) $ in Millions	12 Months Ended
Significant Account Policies (Details) $ in Millions	Dec. 28, 2013 USD ($) number	Dec. 29, 2012 USD ($)	Dec. 31, 2011 USD ($)
Accounting Policies [Abstract]
Minimum number of weeks in the fiscal year (in weeks) \| number	52
Maximum number of weeks in the fiscal year (in weeks) \| number	53
Outstanding checks in excess of funds on deposit classified as accounts payable	$ 39.6	$ 59.4
Direct shipping and handling costs	69.1	64.5	$ 62.5
Advertising and promotional costs	12.2	10.4	13.1
Amount of deferred direct marketing expenses included in other current assets	3.9	3.9
Total distribution network costs	$ 62.2	$ 59.5	$ 59.1

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Property and Equipment [Line Items]
Property and equipment, gross	$ 676,235	$ 627,198
Less accumulated depreciation	(400,347)	(353,740)
Property and equipment, net	275,888	273,458
Property and equipment related depreciation expense	52,900	52,200	$ 53,000
Land [Member]
Property and Equipment [Line Items]
Property and equipment, gross	19,981	13,531
Buildings and permanent improvements [Member]
Property and Equipment [Line Items]
Property and equipment, gross	$ 112,514	112,979
Property and equipment, average useful life (in years)	40 years
Leasehold improvements [Member]
Property and Equipment [Line Items]
Property and equipment, gross	$ 73,974	70,725
Machinery and warehouse equipment [Member]
Property and Equipment [Line Items]
Property and equipment, gross	$ 71,129	68,432
Machinery and warehouse equipment [Member] \| Minimum [Member]
Property and Equipment [Line Items]
Property and equipment, average useful life (in years)	5 years
Machinery and warehouse equipment [Member] \| Maximum [Member]
Property and Equipment [Line Items]
Property and equipment, average useful life (in years)	10 years
Furniture, fixtures and other [Member]
Property and Equipment [Line Items]
Property and equipment, gross	$ 118,806	102,569
Furniture, fixtures and other [Member] \| Minimum [Member]
Property and Equipment [Line Items]
Property and equipment, average useful life (in years)	3 years
Furniture, fixtures and other [Member] \| Maximum [Member]
Property and Equipment [Line Items]
Property and equipment, average useful life (in years)	10 years
Computer equipment and software [Member]
Property and Equipment [Line Items]
Property and equipment, gross	$ 279,831	$ 258,962
Computer equipment and software [Member] \| Minimum [Member]
Property and Equipment [Line Items]
Property and equipment, average useful life (in years)	3 years
Computer equipment and software [Member] \| Maximum [Member]
Property and Equipment [Line Items]
Property and equipment, average useful life (in years)	10 years

Goodwill and Other Intangibles, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Goodwill [Roll Forward]
Beginning Balance	$ 1,601,046	$ 1,497,108
Adjustments to goodwill:
Acquisitions	28,424	92,553
Foreign currency translation	5,535	11,385
Ending Balance	1,635,005	1,601,046	$ 1,497,108
Other intangible assets cost	672,709	685,764
Other intangible assets net	417,133	462,182
Amortization expense related to definite-lived intangible assets	69,200	68,500	58,800
Annual amortization expense expected for 2014	62,600
Annual amortization expense expected for 2015	57,300
Annual amortization expense expected for 2016	51,600
Annual amortization expense expected for 2017	47,900
Annual amortization expense expected for 2018	42,400
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated amortization	(255,576)	(223,582)
Health Care Distribution [Member]
Goodwill [Roll Forward]
Beginning Balance	1,438,922	1,398,248
Adjustments to goodwill:
Acquisitions	22,055	30,765
Foreign currency translation	4,361	9,909
Ending Balance	1,465,338	1,438,922	1,398,248
Technology and Value-Added Services [Member]
Goodwill [Roll Forward]
Beginning Balance	162,124	98,860
Adjustments to goodwill:
Acquisitions	6,369	61,788
Foreign currency translation	1,174	1,476
Ending Balance	169,667	162,124	$ 98,860
Trademarks and tradenames [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]
Indefinite-lived intangibles	3,717	3,681
Non-compete agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	44,162	47,351
Accumulated amortization	(9,666)	(7,949)
Net	$ 34,496	39,402
Non-compete agreements [Member] \| Weighted average [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average useful life (in years)	5 years 7 months 6 days
Trademarks and tradenames [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 77,134	72,948
Accumulated amortization	(27,794)	(18,474)
Net	$ 49,340	54,474
Trademarks and tradenames [Member] \| Weighted average [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average useful life (in years)	8 years 6 months
Customer relationships and lists [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 478,852	504,387
Accumulated amortization	(193,263)	(179,566)
Net	$ 285,589	324,821
Customer relationships and lists [Member] \| Weighted average [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average useful life (in years)	11 years
Other intangibles assets [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 68,844	57,397
Accumulated amortization	(24,853)	(17,593)
Net	$ 43,991	$ 39,804

Investments and Other (Details) - USD ($) $ in Thousands	12 Months Ended
Investments and Other (Details) - USD ($) $ in Thousands	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Investments And Other [Abstract]
Investments in unconsolidated affiliates	$ 205,556	$ 191,075
Non-current deferred foreign, state and local income taxes	48,470	37,737
Notes receivable	10,836	9,851
Auction rate securities, net of temporary impairment	2,654	2,816
Distribution rights and exclusivity agreements, net of amortization	3,321	4,030
Security deposits	3,341	3,291
Debt issuance costs, net of amortization	2,011	7,207
Acquisition related indemnification	13,880	14,168
Acquisition related loan receivable	145,000	0
Other long-term assets	26,876	22,759
Total	$ 461,945	292,934
Minimum percentage of long-term notes receivable interest rates (in hundredths)	2.17%
Maximum percentage of long-term notes receivable interest rates (in hundredths)	12.00%
Latest maturity date of varying installments of long-term notes receivable	Dec. 31, 2020
Amortization expense related to other long-term assets	$ 6,000	$ 4,600	$ 4,000

Debt - Credit Facilities (Details) - USD ($)	12 Months Ended
Debt - Credit Facilities (Details) - USD ($)	Dec. 28, 2013	Sep. 11, 2012
Line of Credit Facility [Line Items]
Weighted average interest rate on borrowings under credit lines at period end (in hundredths)	2.73%
Revolving credit facility [Member]
Line of Credit Facility [Line Items]
Revolving credit facility borrowing capacity	$ 500,000,000	$ 400,000,000
Additional credit available under expansion feature of revolving credit facility	$ 200,000,000	$ 100,000,000
Revolving credit facility expiration date	Sep. 12, 2017
Outstanding letters of credit provided to third parties	$ 10,100,000
Line of credit facility, amount outstanding	0
Various other short-term bank credit lines [Member]
Line of Credit Facility [Line Items]
Line of credit facility, amount outstanding	$ 29,500,000

Debt - Long-term (Details) $ in Thousands	3 Months Ended	12 Months Ended
Debt - Long-term (Details) $ in Thousands	Mar. 30, 2013 USD ($)	Dec. 28, 2013 USD ($)	Dec. 29, 2012 USD ($)	Dec. 31, 2011 USD ($)	Apr. 17, 2013 USD ($)	Feb. 21, 2013 USD ($)	Apr. 30, 2012 USD ($) company	Aug. 10, 2010 USD ($) company
Debt Instrument [Line Items]
Long-term debt and capital lease obligations including current maturities		$ 455,674	$ 506,113
Less current maturities		(5,441)	(17,992)
Total long-term debt		450,233	488,121
Accelerated amortization of deferred financing costs		$ 6,203	0	$ 0
Private placement facilities [Member]
Debt Instrument [Line Items]
Debt instrument maximum borrowing capacity								$ 400,000
Private placement facility additional borrowing capacity							$ 375,000
Number of insurance companies providing private placement facilities (in number of insurance companies) \| company							1	2
Issuance period (in years)		3 years
Long-term debt and capital lease obligations including current maturities		$ 250,000	250,000
Private placement facilities [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities		5 years
Private placement facilities [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities		15 years
Private placement facilities [Member] \| Maximum Average [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities		12 years
Private placement facilities maturing in September 2020 [Member]
Debt Instrument [Line Items]
Date of borrowing		Sep. 02, 2010
Due date		Sep. 02, 2020
Long-term debt and capital lease obligations including current maturities		$ 100,000
Debt instrument, interest rate, stated percentage (in hundredths)		3.79%
Private placement facilities maturing in January 2024 [Member]
Debt Instrument [Line Items]
Date of borrowing		Jan. 20, 2012
Due date		Jan. 20, 2024
Long-term debt and capital lease obligations including current maturities		$ 50,000
Debt instrument, interest rate, stated percentage (in hundredths)		3.45%
Private placement facilities maturing in January 2022 [Member]
Debt Instrument [Line Items]
Date of borrowing		Jan. 20, 2012
Due date		Jan. 20, 2022
Private placement facility annual payment		$ 7,100
Private placement facility annual payment commencement date		Jan. 20, 2016
Long-term debt and capital lease obligations including current maturities		$ 50,000
Debt instrument, interest rate, stated percentage (in hundredths)		3.09%
Private placement facilities maturing in December 2024 [Member]
Debt Instrument [Line Items]
Date of borrowing		Dec. 24, 2012
Due date		Dec. 24, 2024
Long-term debt and capital lease obligations including current maturities		$ 50,000
Debt instrument, interest rate, stated percentage (in hundredths)		3.00%
Notes payable to banks [Member]
Debt Instrument [Line Items]
Long-term debt and capital lease obligations including current maturities		$ 73	11,352
Debt instrument, interest rate, weighted-average percentage (in hundredths)		8.23%
Various uncollateralized loans payable with interest, in varying installments [Member]
Debt Instrument [Line Items]
Long-term debt and capital lease obligations including current maturities		$ 44,091	21,178
Debt instrument interest rate, stated percentage rate range minimum (in hundredths)		2.40%
Debt instrument interest rate, stated percentage rate range maximum (in hundredths)		5.41%
Capital lease obligations [Member]
Debt Instrument [Line Items]
Long-term debt and capital lease obligations including current maturities		$ 1,510	3,144
Henry Schein Animal Health debt [Member]
Debt Instrument [Line Items]
Debt instrument, amount repaid						$ 220,000
Long-term debt and capital lease obligations including current maturities		0	220,439
Debt instrument,unamortized debt discount		0	700
Accelerated amortization of deferred financing costs	$ 6,200
U.S. trade accounts receivable securitization [Member]
Debt Instrument [Line Items]
Debt instrument maximum borrowing capacity					$ 300,000
Long-term debt and capital lease obligations including current maturities		$ 160,000	$ 0
Pricing commitment period		3 years
Commitment fee for facility usage - facility limit greater than or equal to fifty percent usage (as a percent)		0.30%
Commitment fee for facility usage - facility limit less than fifty percent usage (as a percent)		0.35%
U.S. trade accounts receivable securitization [Member] \| Average Asset Backed Commercial Paper Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate at period end		0.96%
Debt instrument, variable rate basis at period end		0.21%
Debt instrument, basis spread on variable rate		0.75%

Debt - Maturities (Details) - USD ($) $ in Thousands	Dec. 28, 2013	Dec. 29, 2012
Maturities of Long-term Debt [Abstract]
2014	$ 5,441
2015	3,223
2016	170,336
2017	17,801
2018	30,302
Thereafter	228,571
Total	$ 455,674	$ 506,113

Redeemable Noncontrolling Interests (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Components of the change in the redeemable noncontrolling interests [Abstract]
Balance, beginning of period	$ 435,175	$ 402,050	$ 304,140
Decrease in redeemable noncontrolling interests due to redemptions	(9,028)	(23,637)	(160,254)
Increase in redeemable noncontrolling interests due to business acquisitions	11,542	30,935	13,618
Net income attributable to redeemable noncontrolling interests	39,430	34,803	36,514
Dividends declared	(19,965)	(21,013)	(15,212)
Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	(654)	904	(889)
Change in fair value of redeemable securities	41,039	53,769	224,133
Other adjustment to redeemable noncontrolling interests	0	(42,636)	0
Balance, end of period	$ 497,539	$ 435,175	$ 402,050

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment	$ (1,503)				$ (849)				$ (1,503)	$ (849)	$ (1,753)
Attributable to Henry Schein, Inc.:
Foreign currency translation gain (loss)	82,288				72,160				82,288	72,160	39,717
Unrealized gain (loss) from foreign currency hedging activities	1,282				1,187				1,282	1,187	(1,678)
Unrealized investment gain (loss)	(515)				(415)				(515)	(415)	(829)
Pension adjustment gain (loss)	(15,206)				(20,077)				(15,206)	(20,077)	(14,626)
Accumulated other comprehensive income (loss)	67,849				52,855				67,849	52,855	22,584
Total Accumulated other comprehensive income (loss)	66,346				52,006				66,346	52,006	20,831
Components of comprehensive income [Abstract]
Net income	$ 134,969	$ 116,372	$ 121,435	$ 98,686	$ 121,715	$ 105,310	$ 107,302	$ 89,061	471,462	423,388	404,656
Foreign currency translation gain (loss)									9,474	33,347	(2,310)
Tax effect									0	0	0
Foreign currency translation gain (loss)									9,474	33,347	(2,310)
Unrealized gain (loss) from foreign currency hedging activities									69	3,519	(712)
Tax effect									26	(654)	94
Unrealized gain (loss) from foreign currency hedging activities									95	2,865	(618)
Unrealized investment gain (loss)									(166)	724	562
Tax effect									66	(310)	(215)
Unrealized investment gain (loss)									(100)	414	347
Pension adjustment gain (loss)									6,207	(7,638)	(7,772)
Tax effect									(1,336)	2,187	1,534
Pension adjustment gain (loss)									4,871	(5,451)	(6,238)
Comprehensive income									$ 485,802	$ 454,563	$ 395,837

Comprehensive Income - Total Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Comprehensive Income Net Of Applicable Taxes [Abstract]
Comprehensive income attributable to Henry Schein, Inc.	$ 446,548	$ 418,347	$ 359,731
Comprehensive income attributable to noncontrolling interests	478	509	481
Comprehensive income attributable to Redeemable noncontrolling interests	38,776	35,707	35,625
Comprehensive income	$ 485,802	$ 454,563	$ 395,837

Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011	Dec. 25, 2010
Fair Value Disclosures [Abstract]
Fair value of debt	$ 485,200	$ 533,300
Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	497,539	435,175	$ 402,050	$ 304,140
Fair value, measurements, recurring [Member] \| Level 1 [Member]
Assets: [Abstracts]
Available-for-sale securities		0
Derivative contracts - assets	0	0
Total assets	0	0
Liabilities: [Abstracts]
Derivative contracts - liabilities	0	0
Total liabilities	0	0
Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 2 [Member]
Assets: [Abstracts]
Available-for-sale securities		0
Derivative contracts - assets	1,235	710
Total assets	1,235	710
Liabilities: [Abstracts]
Derivative contracts - liabilities	1,142	1,159
Total liabilities	1,142	1,159
Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member]
Assets: [Abstracts]
Available-for-sale securities		2,816
Derivative contracts - assets	0	0
Total assets	0	2,816
Liabilities: [Abstracts]
Derivative contracts - liabilities	0	0
Total liabilities	0	0
Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	497,539	435,175
Fair value, measurements, recurring [Member] \| Estimate of fair value measurement [Member]
Assets: [Abstracts]
Available-for-sale securities		2,816
Derivative contracts - assets	1,235	710
Total assets	1,235	3,526
Liabilities: [Abstracts]
Derivative contracts - liabilities	1,142	1,159
Total liabilities	1,142	1,159
Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 497,539	$ 435,175

Business Acquisitions, Divestiture and Other Transaction - Acquisitions (Details) - USD ($) $ in Thousands		12 Months Ended
	Dec. 31, 2010	Dec. 31, 2013	Jun. 30, 2010	Jan. 06, 2014	Dec. 30, 2013	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Business Acquisition [Line Items]
Business acquisition allocated goodwill amount						$ 1,635,005	$ 1,601,046	$ 1,497,108
Long-term loan funding provided						145,000	0
Arseus NV Legal Entity [Member]
Business Acquisition [Line Items]
Business acquisition, aggregate sales in year of acquisition of acquired companies		$ 97,000
BioHorizons, Inc. Legal Entity [Member]
Business Acquisition [Line Items]
Business acquisition, aggregate sales in year of acquisition of acquired companies		$ 115,000
Provet Holdings Limited Legal Entity [Member]
Business Acquisition [Line Items]
Business acquisition, aggregate sales in year of acquisition of acquired companies			$ 278,000
Arseus NV [Member]
Business Acquisition [Line Items]
Acquired equity interest (in hundredths)				100.00%
BioHorizons, Inc. [Member]
Business Acquisition [Line Items]
Acquired equity interest (in hundredths)					60.00%
Long-term loan receivable reclassified to intercompany loans					$ 145,000
BioHorizons, Inc. [Member] \| Funding provided to acquiree prior to acquisition [Member]
Business Acquisition [Line Items]
Long-term loan funding provided						145,000
Provet Holdings Limited [Member]
Business Acquisition [Line Items]
Acquired equity interest (in hundredths)	100.00%
Cash consideration paid	$ 91,000
Business acquisition allocated goodwill amount	$ 27,000
Other acquisitions immaterial individually and in the aggregate [Member]
Business Acquisition [Line Items]
Business acquisition allocated goodwill amount						$ 14,700	$ 128,000	$ 38,800

Business Acquisitions, Divestiture and Other Transaction - Divestiture and Other (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended	12 Months Ended
	Aug. 03, 2009	Sep. 28, 2013	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011	Sep. 30, 2013	Dec. 12, 2008
Schedule of Equity Method Investments [Line Items]
Loss on sale of equity investment			$ (12,535)	$ 0	$ 0
Payments related to sale of equity investment			$ 13,364	$ 0	$ 0
Middle East equity affiliate [Member]
Schedule of Equity Method Investments [Line Items]
Loss on sale of equity investment		$ 12,500
Loss on sale of equity investment per diluted share		$ 0.14
Payments related to sale of equity investment		$ 13,400
D4D Technologies [Member]
Schedule of Equity Method Investments [Line Items]
Conversion to equity interest in D4D Technologies, LLC							$ 10,400
Equity interest in D4D Technologies, LLC (in hundredths)						21.40%	15.33%
Payment made under amendment to agreement to certain of D4D's members	$ 8,000
Period over which initial payment with amendment is being amortized (in years)	15 years

Plans of Restructuring (Details) $ in Thousands	12 Months Ended
Plans of Restructuring (Details) $ in Thousands	Dec. 28, 2013 USD ($)	Dec. 29, 2012 USD ($) number	Dec. 31, 2011 USD ($)
Restructuring and Related Activities [Abstract]
Positions eliminated from operations (in positions) \| number		200
Restructuring costs	$ 0	$ 15,192	$ 0
Restructuring costs after-tax		10,500
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance	3,057	1,120	4,343
Provision	0	15,192	0
Payments and other adjustments	(2,346)	(13,255)	(3,223)
Restructuring Reserve, ending balance	711	3,057	1,120
Health Care Distribution [Member]
Restructuring and Related Activities [Abstract]
Restructuring costs	0	14,981	0
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance	3,043	1,120	4,343
Provision	0	14,981	0
Payments and other adjustments	(2,332)	(13,058)	(3,223)
Restructuring Reserve, ending balance	711	3,043	1,120
Technology and Value-Added Services [Member]
Restructuring and Related Activities [Abstract]
Restructuring costs	0	211	0
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance	14	0	0
Provision	0	211	0
Payments and other adjustments	(14)	(197)	0
Restructuring Reserve, ending balance	0	14	0
Severance costs [Member]
Restructuring and Related Activities [Abstract]
Restructuring costs	0	12,841	0
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance	1,826	569	1,992
Provision	0	12,841	0
Payments and other adjustments	(1,599)	(11,584)	(1,423)
Restructuring Reserve, ending balance	227	1,826	569
Facility closing costs [Member]
Restructuring and Related Activities [Abstract]
Restructuring costs	0	2,351	0
Restructuring Reserve [Roll Forward]
Restructuring Reserve, beginning balance	1,231	551	2,351
Provision	0	2,351	0
Payments and other adjustments	(747)	(1,671)	(1,800)
Restructuring Reserve, ending balance	$ 484	$ 1,231	$ 551

Earnings Per Share (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Weighted-average common shares outstanding:
Basic (in shares)	85,926	87,499	90,120
Effect of dilutive securities:
Stock options, restricted stock and restricted stock units (in shares)	1,696	2,324	2,500
Diluted (in shares)	87,622	89,823	92,620
Weighted-average options to purchase shares - anti-dilutive (in shares)			8
Weighted-average price per common stock (in dollars per share)			$ 69.45

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Income before taxes, equity in earnings of affiliates and loss on sale of equity investment [Abstract]
Domestic	$ 517,950,000	$ 466,457,000	$ 403,171,000
Foreign	146,744,000	137,731,000	166,136,000
Total	664,694,000	604,188,000	569,307,000
Current income tax expense:
U.S. Federal	139,253,000	121,591,000	125,148,000
State and local	27,272,000	23,279,000	30,423,000
Foreign	35,880,000	32,916,000	43,960,000
Total current	202,405,000	177,786,000	199,531,000
Deferred income tax expense (benefit):
U.S. Federal	10,325,000	9,242,000	(12,466,000)
State and local	(4,531,000)	946,000	(1,782,000)
Foreign	(17,308,000)	(116,000)	(5,071,000)
Total deferred	(11,514,000)	10,072,000	(19,319,000)
Total provision	190,891,000	187,858,000	180,212,000
Current deferred income tax assets:
Inventory, premium coupon redemptions and accounts receivable valuation allowances	31,016,000	27,820,000
Uniform capitalization adjustments to inventories	7,318,000	9,944,000
Other current assets	21,351,000	21,035,000
Current deferred income tax asset	59,685,000	58,799,000
Non-current deferred income tax asset (liability):
Property and equipment	(5,571,000)	(5,661,000)
Stock-based compensation	35,995,000	42,875,000
Other non-current liabilities	(211,180,000)	(215,562,000)
Net operating losses of domestic subsidiaries	693,000	2,768,000
Net operating losses of foreign subsidiaries	45,254,000	47,101,000
Total non-current deferred tax liability	(134,809,000)	(128,479,000)
Valuation allowance for non-current deferred tax assets	(16,285,000)	(30,598,000)
Net non-current deferred tax liability	(151,094,000)	(159,077,000)
Net deferred income tax liability	(91,409,000)	(100,278,000)
Income Tax Expense (Benefit), Income Tax Reconciliation [Abstract]
Income tax provision at federal statutory rate	232,644,000	211,466,000	199,256,000
State income tax provision, net of federal income tax effect	20,134,000	21,665,000	18,035,000
Foreign income tax benefit	(19,635,000)	(17,979,000)	(20,169,000)
Valuation allowance	(14,026,000)	1,502,000	442,000
Interest expense related to loans	(23,723,000)	(21,018,000)	(14,394,000)
Other	(4,503,000)	(7,778,000)	(2,958,000)
Total income tax provision	$ 190,891,000	$ 187,858,000	180,212,000
Effective tax rate (in hundredths)	28.70%	31.10%
Valuation allowance, deferred tax asset, change in amount	$ 13,400,000
Effective tax rate without effect of reduction in valuation allowance (in hundredths)	30.70%
Cummulative amount of reinvested earnings	$ 694,200,000
Unrecognized tax benefits	54,100,000
Unrecognized tax benefits that would affect the effective tax rate if recognized	40,300,000
Total interest	10,900,000
Total penalites	0
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance, beginning of period	32,700,000	$ 19,200,000
Additions based on current year tax positions	6,000,000	4,900,000
Additions based on prior year tax positions	9,600,000	11,200,000
Reductions based on prior year tax positions	(1,100,000)	(600,000)
Reductions resulting from settlements with taxing authorities	(800,000)	(1,300,000)
Reductions resulting from lapse in statutes of limitations	(3,200,000)	(700,000)
Balance, end of period	43,200,000	$ 32,700,000	$ 19,200,000
State net operating loss carryforwards [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 6,900,000
Net operating loss carryforwards, year of expiration	Dec. 31, 2029
Foreign net operating loss carryforwards [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 11,700,000
Net operating loss carryforwards not subject to expiration	$ 153,100,000
Net operating loss carryforwards, year of expiration	Dec. 31, 2019

Concentrations of Risk (Details)	12 Months Ended
Concentrations of Risk (Details)	Dec. 28, 2013
Top customer concentration risk [Member] \| Sales revenue, net [Member] \| Any single customer [Member] \| Maximum [Member]
Concentration Risk [Line Items]
Concentration risk percentage (in hundredths)	0.80%
Supplier Concentration Risk [Member] \| Cost of goods, total [Member] \| Top ten health care distribution suppliers [Member]
Concentration Risk [Line Items]
Concentration risk percentage (in hundredths)	37.00%
Supplier Concentration Risk [Member] \| Cost of goods, total [Member] \| Single largest supplier [Member]
Concentration Risk [Line Items]
Concentration risk percentage (in hundredths)	8.00%

Segment Data (Details)	3 Months Ended								12 Months Ended
Segment Data (Details)	Dec. 28, 2013 USD ($) number	Sep. 28, 2013 USD ($)	Jun. 29, 2013 USD ($)	Mar. 30, 2013 USD ($)	Dec. 29, 2012 USD ($)	Sep. 29, 2012 USD ($)	Jun. 30, 2012 USD ($)	Mar. 31, 2012 USD ($)	Dec. 28, 2013 USD ($) number	Dec. 29, 2012 USD ($)	Dec. 31, 2011 USD ($)
Segment Reporting [Abstract]
Number of reportable segments \| number									2
Number of countries served globally \| number	25								25
Goodwill impairment loss										$ 0
Segment Reporting Information [Line Items]
Net sales	$ 2,526,370,000	$ 2,348,956,000	$ 2,391,810,000	$ 2,293,511,000	$ 2,408,438,000	$ 2,231,058,000	$ 2,201,452,000	$ 2,099,019,000	$ 9,560,647,000	8,939,967,000	$ 8,530,242,000
Operating income	186,883,000	$ 160,477,000	$ 176,065,000	$ 153,629,000	181,342,000	$ 149,622,000	$ 154,702,000	$ 133,295,000	677,054,000	618,961,000	582,149,000
Income before taxes, equity in earnings of affiliates and loss on sale of equity investment									664,694,000	604,188,000	569,307,000
Depreciation and amortization									128,035,000	125,322,000	115,896,000
Income taxes									190,891,000	187,858,000	180,212,000
Interest income									12,853,000	13,394,000	15,593,000
Interest expense									27,538,000	30,902,000	30,377,000
Purchases of fixed assets									60,215,000	51,237,000	45,176,000
Total assets	5,624,636,000				5,333,997,000				5,624,636,000	5,333,997,000	4,740,144,000
Health Care Distribution [Member]
Segment Reporting Information [Line Items]
Net sales									9,240,600,000	8,656,554,000	8,279,622,000
Operating income									590,664,000	541,667,000	512,094,000
Income before taxes, equity in earnings of affiliates and loss on sale of equity investment									581,759,000	529,236,000	501,266,000
Depreciation and amortization									113,670,000	113,688,000	106,485,000
Income taxes									165,869,000	165,346,000	157,391,000
Interest income									12,816,000	13,293,000	15,531,000
Interest expense									27,375,000	30,790,000	30,350,000
Purchases of fixed assets									57,364,000	47,057,000	42,751,000
Total assets	5,277,354,000				5,001,188,000				5,277,354,000	5,001,188,000	4,542,331,000
Health Care Distribution [Member] \| Dental [Member]
Segment Reporting Information [Line Items]
Net sales									4,997,972,000	4,774,482,000	4,764,898,000
Health Care Distribution [Member] \| Animal Health [Member]
Segment Reporting Information [Line Items]
Net sales									2,599,461,000	2,321,151,000	2,010,270,000
Health Care Distribution [Member] \| Medical [Member]
Segment Reporting Information [Line Items]
Net sales									1,643,167,000	1,560,921,000	1,504,454,000
Technology and Value-Added Services [Member]
Segment Reporting Information [Line Items]
Net sales									320,047,000	283,413,000	250,620,000
Operating income									86,390,000	77,294,000	70,055,000
Income before taxes, equity in earnings of affiliates and loss on sale of equity investment									82,935,000	74,952,000	68,041,000
Depreciation and amortization									14,365,000	11,634,000	9,411,000
Income taxes									25,022,000	22,512,000	22,821,000
Interest income									37,000	101,000	62,000
Interest expense									163,000	112,000	27,000
Purchases of fixed assets									2,851,000	4,180,000	2,425,000
Total assets	$ 347,282,000				$ 332,809,000				$ 347,282,000	$ 332,809,000	$ 197,813,000

Segment Data - Net Sales and Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 2,526,370	$ 2,348,956	$ 2,391,810	$ 2,293,511	$ 2,408,438	$ 2,231,058	$ 2,201,452	$ 2,099,019	$ 9,560,647	$ 8,939,967	$ 8,530,242
Long-lived assets	2,328,026				2,336,686				2,328,026	2,336,686	2,168,808
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									5,813,512	5,496,969	5,212,861
Long-lived assets	1,272,683				1,313,866				$ 1,272,683	$ 1,313,866	$ 1,279,913
United States [Member] \| Geographic concentration risk [Member] \| Sales revenue, net [Member] \| Minimum [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage (in hundredths)									10.00%	10.00%	10.00%
Locations other than the United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									$ 3,747,135	$ 3,442,998	$ 3,317,381
Long-lived assets	$ 1,055,343				$ 1,022,820				$ 1,055,343	$ 1,022,820	$ 888,895

Employee Benefit Plans - Stock-based Compensation (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Compensation Related Costs [Abstract]
Pre-tax share-based compensation expense	$ 35,500	$ 37,300	$ 36,900
After-tax share-based compensation expense	24,600	25,700	25,200
Excess tax benefits	8,141	17,819	8,765
Liability for cash settlement stock-based compensation awards	545	$ 551	$ 659
Fair value adjustment for cash settlement stock-based compensation awards	$ 600
Weighted-average grant date fair value of stock-based awards granted before forfeitures (in dollars per share)	$ 89.97	$ 73.42	$ 68.25
Total unrecognized compensation cost related to non-vested awards	$ 69,800
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)	2 years
Total cash received as a result of stock options exercises	$ 35,553	$ 72,485	$ 34,519
Stock option exercises tax benefits	$ 18,410	$ 31,638	$ 7,246
Employee and director stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent annual vesting of stock option awards (in hundredths)	25.00%
Contractual term of stock options from the grant date (in years)	10 years
Number of years for full vesting (in years)	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	2,138	4,059	5,012
Granted (in shares)	0	0	10
Exercised (in shares)	(815)	(1,890)	(942)
Forfeited (in shares)	0	(31)	(21)
Outstanding at end of period (in shares)	1,323	2,138	4,059
Ending balance, options exercisable (in shares)	1,323	2,137	3,778
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)	$ 48.61	$ 44.53	$ 43.05
Granted (in dollars per share)	0	0	69.45
Exercised (in dollars per share)	43.86	40.06	36.84
Forfeited (in dollars per share)	0	36.02	48.35
Outstanding at end of period (in dollars per share)	51.53	48.61	44.53
Ending balance, options exercisable (in dollars per share)	$ 51.53	$ 48.62	$ 43.47
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected dividend yield (in hundredths)			0.00%
Expected stock price volatility (in hundredths)			20.00%
Risk-free interest rate (in hundredths)			2.13%
Expected life of options (years)			4 years 9 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Stock option oustanding aggregate intrinsic value as of period end	$ 83,252	$ 67,044	$ 80,821
Stock option exercisable aggregate intrinsic value as of period end	$ 83,252	$ 66,964	$ 79,202
Restricted stock/units [Member]
Non Vested Restricted Shares Units [Abstract]
Intrinsic value of restricted stock that vested during the year (in dollars per share)	$ 98.99	$ 75.98	$ 66.78
Time-based restricted stock/units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Beginning balance outstanding (in shares)	1,018
Granted (in shares)	217
Vested (in shares)	(280)
Forfeited (in shares)	(29)
Ending balance outstanding (in shares)	926	1,018
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Beginning balance outstanding (in dollars per share)	$ 56.87
Granted (in dollars per share)	90.23
Vested (in dollars per share)	35.59
Forfeited (in dollars per share)	70.06
Ending balance outstanding (in dollars per share)	70.70	$ 56.87
Intrinsic value (in dollars per share)	$ 114.43
Performance-based restricted stock/units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	3 years
Period over which earnings per share performance is measured against specified targets (in years)	three
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Beginning balance outstanding (in shares)	1,315
Granted (in shares)	149
Vested (in shares)	(363)
Forfeited (in shares)	(23)
Ending balance outstanding (in shares)	1,078	1,315
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Beginning balance outstanding (in dollars per share)	$ 53.27
Granted (in dollars per share)	83.34
Vested (in dollars per share)	56.55
Forfeited (in dollars per share)	74.78
Ending balance outstanding (in dollars per share)	59.85	$ 53.27
Intrinsic value (in dollars per share)	$ 114.43
2013 Stock Incentive Plan, as amended [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized to be granted (in shares)	31,229
Shares available to be granted (in shares)	6,583
1996 Non-Employee Director Stock Incentive Plan, as amended [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized to be granted (in shares)	800
Shares available to be granted (in shares)	93

Employee Benefit Plans - Other Employee Benefits (Details) - USD ($)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Management [Member] \| Deferred compensation bonus and commission plan [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation plan fair market value amount charged (credited) to operations	$ 1,100,000	$ 300,000	$ 0
Qualified 401K plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Amounts charged (credited) to operations	$ 25,300,000	23,800,000	23,000,000
Qualified 401K plan [Member] \| Maximum [Member]
Defined Contribution Plan Disclosure [Line Items]
Maximum matching contributions as a percentage of participants' contributions (in hundredths)	100.00%
Maximum participants' contributions as a percentage of their base compensation (in hundredths)	7.00%
Allowable maximum percentage of contributions allocated to Henry Schein Stock Fund (in hundredths)	20.00%
Supplemental executive retirement plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Amounts charged (credited) to operations	$ 4,100,000	$ 2,100,000	$ 700,000

Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2014	$ 75,394
2015	61,238
2016	45,154
2017	32,369
2018	26,497
Thereafter	61,680
Total minimum operating lease payments	302,332
Total rent expense	70,800	$ 68,200	$ 65,500
Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2014	847
2015	487
2016	269
2017	35
2018	0
Thereafter	0
Total minimum capital lease payments	1,638
Less: Amounts representing interest	(128)
Total present value of minimum capital lease payments	$ 1,510
Capital leases, minimum interest percentage (in hundredths)	2.00%
Capital leases, maximum interest percentage (in hundredths)	16.44%
Contractual Obligation, Fiscal Year Maturity [Abstract]
Capital expenditure commitment due within one year	$ 1,600
Unrecorded Unconditional Purchase Obligation, Fiscal Year Maturity [Abstract]
2014	41,920
2015	22,076
2016	22,457
2017	23,580
2018	24,759
Thereafter	53,294
Total minimum inventory purchase commitment payments	188,086
Employment, consulting and non-compete agreements [Member]
Other Commitment, Fiscal Year Maturity [Abstract]
2014	13,000
2015	2,700
2016	2,100
2017	2,500
2018	200
Thereafter	2,200
Life-time consulting agreement [Member]
Other Commitment, Fiscal Year Maturity [Abstract]
Current compensation paid under lifetime consulting agreement	500
Amount of increase effective every fifth year on lifetime consulting agreement	$ 25

Quarterly Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Quarterly Financial Data [Abstract]
Net sales	$ 2,526,370	$ 2,348,956	$ 2,391,810	$ 2,293,511	$ 2,408,438	$ 2,231,058	$ 2,201,452	$ 2,099,019	$ 9,560,647	$ 8,939,967	$ 8,530,242
Gross profit	699,520	639,647	669,856	646,991	663,495	609,044	624,395	610,579	2,656,014	2,507,513	2,418,055
Operating income	186,883	160,477	176,065	153,629	181,342	149,622	154,702	133,295	677,054	618,961	582,149
Net income	134,969	116,372	121,435	98,686	121,715	105,310	107,302	89,061	471,462	423,388	404,656
Amounts attributable to Henry Schein, Inc.:
Net income	$ 124,268	$ 107,378	$ 108,430	$ 91,478	$ 112,467	$ 96,771	$ 98,086	$ 80,752	$ 431,554	$ 388,076	$ 367,661
Earnings per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 1.46	$ 1.25	$ 1.26	$ 1.06	$ 1.29	$ 1.11	$ 1.11	$ 0.92	$ 5.02	$ 4.44	$ 4.08
Diluted (in dollars per share)	$ 1.43	$ 1.23	$ 1.23	$ 1.03	$ 1.26	$ 1.08	$ 1.08	$ 0.89	$ 4.93	$ 4.32	$ 3.97

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Supplemental Cash Flow Information [Abstract]
Interest	$ 19,893	$ 23,358	$ 30,847
Income taxes	146,593	196,765	173,318
Unrealized gain (loss) from foreign currency hedging activities	69	3,519	(712)
Debt assumed as part of acquisitions	$ 100	$ 8,300	$ 16,700

Schedule II - Valuation and Qualifying Accounts (Details) - Allowance for doubtful accounts, sales returns and other [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 75,240	$ 65,853	$ 56,267
Charged to statement of income	5,189	4,407	6,156
Charged to other accounts	6,195	13,305	9,665
Deductions	(8,326)	(8,325)	(6,235)
Balance at end of period	$ 78,298	$ 75,240	$ 65,853